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make an informed choice. I describe the many human, educational and technological aspects that must
be considered in developing an alternative method to the written informed consent process. I have
developed a tutorial that can be tested within the clinical trial to compare the differences in informed
consent methods. The research community is obligated to improve the informed consent process and
these preliminary efforts are worthy of further development.
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ABSTRACT
Standard research practice has been to protect the rights of human
subjects by providing an informed consent document that explains the study in
clear and concise language. The problems inherent in writing this document are
considerable and it is not known how effective these documents are in providing
information and enhancing understanding about research participation.
I have selected a clinical research trial involving older men to illustrate the
challenge of providing sufficient information so that a person can make an
informed choice. I describe the many human, educational and technological
aspects that must be considered in developing an alternative method to the
written informed consent process. I have developed a tutorial that can be tested
within the clinical trial to compare the differences in informed consent methods.
The research community is obligated to improve the informed consent process
and these preliminary efforts are worthy of further development.
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CHAPTER 1
INTRODUCTION
History of Human Subjects and Informed Consent for Clinical Research
The history of human subject protection in clinical research in the United
States has several important milestones. In 1906 the United States Congress
passed the Food and Drug Act to address concerns about the quality and safety
of food and medicines. The Nuremberg Code was written in 1947 in response to
human experiments conducted during World War II. This code became the
foundation of the Code of Federal Regulations, Title 45-Public Welfare, Part 46Protection of Human Subjects (45 CFR 46). In 1962 Congress passed the
Kefauver-Harris Amendments to ensure drug efficacy and greater drug safety,
and in what was the initial acknowledgement of the rights and voices of
consumers, the Consumer Bill of Rights. In 1973, the Consumer Product Safety
Commission was established, followed by the Bioresearch Monitoring program in
1977, which focused on protection of human subjects. In 1981, 45 CFR 46 was
revised to focus specifically on the elements of informed consent (Milestones in
US Food and Drug Law History, 2005).
In parallel to these events, medical science was exploring new research
methods. The clinical trial emerged in the late 1950’s as the valid and objective
research method to test the safety and efficacy of medical treatment. A clinical
trial is defined as an experiment testing medical treatments on human subjects.
Medical science has relied on this standard for almost five decades (Pianttadosi,
1997).
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Federal standards established and refined over the last century to regulate
drug and device development have generated enormous growth within the
pharmaceutical industry. Standards of medical care have changed to integrate
the information that is generated from clinical trials in the name of improved
health care and patient safety. For example, mammography and colonoscopy,
originally used as diagnostic tests, are now used as routine screening tests
intended to detect early changes that could result in breast or colon cancer.
The process of conducting research to inform medical care, however, is
dependent on people to participate as subjects. Without people to volunteer for
clinical research, medical science would not know enough about the effects of
drugs on humans and therefore would not have the essential information needed
to advance medical knowledge and ultimately improve public health. Animal and
laboratory studies can provide data but only human beings can provide
subjective information about the signs and symptoms associated with how a drug
or device makes them feel.
Throughout the history of medical research there have been several
identified instances of misconduct wherein the rights of research participants
were purposefully violated by those entrusted with their protection. One such
instance occurred in Tuskegee, Alabama. Between 1932 and 1972, the United
States Public Health Service (PHS) physicians and researchers conducted a
study of African-American men with syphilis. Though it was discovered in 1940
that penicillin could cure syphilis, treatment was purposely withheld from these
men so that the research study was allowed to continue in order to further
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evaluate the impact of the untreated disease. Three hundred ninety-nine men
were told they had “bad blood” and were continuously misled about their health
and subjected to many unnecessary and often risky medical procedures.
Because these men were poor and had limited access to healthcare, researchers
at Tuskegee were able to exercise control over what happened to these subjects.
Worse, when 250 of these men registered for the draft during World War II and
were ordered to get treatment for syphilis, the PHS intervened and had them
exempted from this requirement. The experiment came to an end only when it
gained media attention in 1972. By then many of the wives, partners and children
of these men had contracted the disease and almost half of the men had died
from syphilis or its complications (Jones, 1981). One of the consequences of this
tragedy was the strong mistrust of the medical establishment that developed and
persists among many African-Americans (Braunstein, 2008).
Several other instances of unethical research were exposed by Dr. Henry
K. Beecher, a professor of anesthesiology at Harvard Medical School. In 1966,
Dr. Beecher published an article in the New England Journal of Medicine that
gained attention outside of the medical community. He cited 22 examples of
unethical research that violated the principle of voluntary consent in human
subjects research. This article emphasized the thoughtless, as opposed to the
willful disregard that researchers had toward some human subjects and
heightened the awareness of researchers, the public and the press to the
problem of unethical human subject research.
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These disclosures coincided with professional and governmental action to
curb unethical research practices. In 1964, the Declaration of Helsinki was
developed by the World Medical Association (WMA) which established a set of
ethical principles for the conduct of human research. In 1966 the American
Medical Association (AMA) released Ethical Guidelines for Clinical Investigation,
and the National Institutes of Health (NIH) published rules applicable to all
federally funded human subject research. In 1981, additional laws and guidelines
were specified to ensure the protection of human subjects in sections of the U.S.
Code of Federal Regulations (CFR) and the International Committee on
Harmonization (ICH) Guideline for Good Clinical Practice (NCI Guide to
Understanding Informed Consent, 2001).
The ICH GCP Guidelines have been established as the ethical and
scientific quality standard and have their origin in the Declaration of Helsinki (ICH
Guidance for Industry, 1996). The underlying ethical principles in these
guidelines are that research must be conducted with the well-being of subjects as
the most important consideration and that the research goals must be
scientifically sound and focused on improving clinical outcome. Embedded in
these guidelines, which have been adopted by the United States, Canada, Japan
and the European Union, is recognition of the obligation of researchers to fully
disclose information about the potential risks and benefits of research, as well as
respect for the autonomy of individuals to make informed decisions based on full
disclosure of this information (Sharp, 2004). It is this obligation that has led to
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additional oversight to the protection of human subjects and the informed
consent process.
These codes and guidelines are based on the assumption that all involved
parties are knowledgeable about research quality and ethics and are fully
committed to their application, which is not necessarily the case. Academic
medical centers have established Institutional Review Boards (IRB) composed of
medical researchers and non-research members who are charged with
protecting the rights and welfare of human subjects recruited into research
studies. Because of the unique composition of this board, which includes
physicians, nurses, researchers, and patient representatives, the IRB is well
suited to evaluate each research study and the human subject informed consent
documents that are written to accompany the research protocol. IRBs are
granted the authority to disapprove or modify a research study based on human
subject protections (45 Code of Federal Regulations 46, Subpart A, 2005).
Though these ideal standards have been available to guide the conduct and
review of medical research, the implementation of these research standards is
often flawed at the organizational level.
In 1999, a young man who voluntarily participated in an experimental gene
therapy study at the University of Pennsylvania (Penn) died, not from his
underlying medical condition but as a direct result of administration of a gene
transfer product. This prompted a thorough examination of the entire medical
research arena at Penn and within the Department of Health and Human
Services (DHHS). DHHS suspended all gene transfer research at Penn and
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other academic institutions nationally and convened an advisory committee on
Oversight of Clinical Gene Transfer Research. Their recommendations focused
on establishing rigorous requirements for accountability, reporting and
transparency in all aspects of the scientific conduct of gene transfer research
(Enhancing the Protection of Human Subjects in Gene Transfer Research at NIH,
2000). Prior to this occurrence, the research administration at Penn functioned in
an arena that had cursory oversight to the activities of individual researchers. It
subsequently introduced more stringent standards and accountability for training,
documentation, and inspection across the School of Medicine that had not
previously existed.
As a result of increasing awareness about the need to ensure safety of
research subjects, as well as to compel researchers to register research
activities, and document compliance with established Federal guidelines, the
School of Medicine established the Office of Human Research to provide
education and training about all aspects of conducting sound, safe research. This
office was charged with developing activities that ensure the protection of human
subjects and was authorized to oversee the specific procedures and methods
being used across the university. In establishing itself as the local government
proxy, the University would be able to evaluate research practices before the
U.S. Government had reason to do so. One of the benefits is the heightened
awareness that investigators and their staff have about human subject safety and
their increased attention to the process of obtaining informed consent.
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Though U.S. federal regulations specify eight elements of information that
must be disclosed to research participants, (see Table 1), ethically valid informed
consent demands more than just disclosure and as such, presents several
challenges to the researcher (Flory, 2004).
Table 1. Department of Health and Human Services (45 CFR 46.116)
Essential Elements of Informed Consent
Except as provided in paragraph (c) or (d) of this section, in seeking informed
consent, the following information shall be provided to each subject:
1. A statement that the study involves research, an explanation of the
purposes of the research and the expected duration of the subject's
participation, a description of the procedures to be followed, and
identification of any procedures which are experimental;
2. A description of any reasonably foreseeable risks or discomforts to the
subject;
3. A description of any benefits to the subject or to others which may
reasonably be expected from the research;
4. A disclosure of appropriate alternative procedures or courses of treatment,
if any, that might be advantageous to the subject;
5. A statement describing the extent, if any, to which confidentiality of records
identifying the subject will be maintained;
6. For research involving more than minimal risk, an explanation as to
whether any compensation and an explanation as to whether any medical
treatments are available if injury occurs and, if so, what they consist of, or
where further information may be obtained;
7. An explanation of whom to contact for answers to pertinent questions
about the research and research subjects' rights, and whom to contact in
the event of a research-related injury to the subject; and
8. A statement that participation is voluntary, refusal to participate will involve
no penalty or loss of benefits to which the subject is otherwise entitled, and
the subject may discontinue participation at any time without penalty or
loss of benefits to which the subject is otherwise entitled.

Writing an informed consent document requires meeting at least four
objectives. It must be (1) compliant with regulations and institutional legal
requirements; (2) accurate; (3) informative; and (4) understandable (Sharp,
2006). To write this document at a level of readability (defined as the ease with
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which printed material can be read) that is at or below the eighth-grade level,
which is the NIH recommendation that has been adopted by most institutional
review boards, can be difficult (NCI Simplification of Informed Consent
Documents, 2006). In a review of informed consent documents of 18 cancer
clinical trials, Sharp (2004) found that only 1.0% of the informed consent
documents were written at the eighth-grade level and that over the last decade
most consent forms have become longer and more difficult to read.
Researchers and bioethicists have recognized this problem of reading
difficulty. Explaining a complicated research project in simple language in many
pages of printed text does not ensure that it will be understood. There are many
variables to consider including the educational level of the participant, differences
in learning style; language used; and the medical urgency or level of illness
(Jimison, 1998). If people do not understand what they are agreeing to, being
informed is not assured.
Purpose of Thesis
I have selected a clinical trial that is being developed at the University of
Pennsylvania, School of Medicine, to illustrate the challenge of providing
sufficient information so that a person can make an informed choice about
participating in a research study. I propose developing a multimedia tool to
enhance the informed consent process by providing information in a familiar and
accessible format instead of the standard paper document. In Chapter 2, I
provide relevant information from medical literature that describes the problem of
measuring the outcome of the informed consent process. There is little literature
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on this topic and a confounding factor is the difficulty in discerning what is
remembered versus what is understood. In Chapter 3, I explore the important
human considerations that may be encountered in this complex clinical trial of
older men. Chapter 4 describes the methods employed in developing the tutorial.
Chapter 5 contains my conclusions about the final product, reflections on how it
may enhance the informed consent process as well as the potential for
acceptance as a useful tool in clinical research.
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CHAPTER 2
DESCRIPTION OF THE INFORMED CONSENT PROBLEM
The informed consent document is the starting point for the dynamic
process and exchange of information that occurs between the physician/research
team and the potential participant over the course of the research experience
(NCI Simplification of Informed Consent Documents, 2006). A review of the
literature on the topic of informing patients for the purpose of obtaining consent
(for medical treatment or research participation) indicates that there is not a great
deal of quantitative research available.
Flory (2004) reported a meta-analysis of 12 studies that compared the
understanding of participants who had undergone a standard informed consent
process to participants who had received an intervention to improve their
understanding. The samples included adult men and women of all ages who
were parents of pediatric patients, oncology patients, psychiatric patients, IV drug
users, pregnant women and healthy volunteers. The interventions (defined as
information delivery methods) varied among the 12 studies and included
PowerPoint presentations, video, text reformatting as a booklet, and readability
reduced to the 7th grade reading level. The results showed a consistent
demographic predictor: research participants with higher education or reading
levels had significantly higher level of understanding of information presented in
the informed consent process, based on a post consent assessment. The results
also indicated that levels of satisfaction were highest among participants who
perceived that they had extended discussion time about the consent form (Flory,
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2004). This suggests that the experience of discussion or personal interaction
plays an important role among subjects who are considering participating. This
resonates with bioethicists and medical researchers who emphasize the
importance of conducting informed consent as a process and not just a form that
requires a signature (Lavori, 1999).
Agre (2003) analyzed eight studies of informed consent interventions that
included modified print, computer and video consent formats and knowledge
quizzes among adults. The mean age was 60 years; 57% were men. The
findings were that better educated subjects scored better in the knowledge
quizzes and that computer and video consent formats produced improvements in
understanding over standard text media. These subjects also reported that the
video clips of patients were the most useful part of the computer intervention.
Wirshing (2005) reported a study comparing 261 adult medical and
psychiatric patients who viewed a videotape that explained the informed consent
process and emphasized good decision making in considering research
participation, with a control group of healthy volunteers. The videotape
repeatedly emphasized the need for subjects to be assertive in seeking
information, and included role-playing vignettes of doctors and patients that
reinforced the subject’s right to know and the physician’s responsibilities in
providing clear explanations of the research procedures during the informed
consent process. Results showed larger gains in knowledge among those who
viewed the video about informed consent when measured before and after the
process, as compared to the control group.
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Hitchcock-Bryan (2007) reported a study of 77 cancer research patients
who participated in an evaluation of an informed consent video. A post consent
analysis indicated that watching the video did not measurably improve the
subjects’ understanding of cancer clinical trials. However, subjects reported that
the video provided important information, helped them educate their families and
improved communication with their provider (Hitchcock-Bryan, 2007). This
suggests that subjects perceived increased value and meaning despite a lack of
benefit on the measured assessment of knowledge.
Jimison (1998) designed a study that approached patients as consumers
who demand a greater choice and involvement in their healthcare. A needs
assessment was conducted around the topic of informed consent for medical
treatment that included feedback from focus groups and individual interviews with
medical and psychiatric patients. The primary findings indicated that most
patients felt that the consent forms were too long, that the wording was too
complex and that the level of detail was confusing. Patients reported that they
preferred information presented to them in smaller segments and felt that the use
of video made the information more understandable and the situation less
stressful. Patients reported that one source of the stress occurred due to difficulty
in concentrating on the printed text. The authors concluded that the use of a
multimedia tool that offered the ability to proceed through the material at a selfselected pace made the material more interesting to the patient and reduced
dependence on the patient’s ability to read. Such a tool may have the potential to
enhance and standardize the quality of the informed consent process. Since so
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little is understood about how to make the process effective, however, the
authors recommended that the patients or volunteers needs must be understood
before a multimedia approach could be designed to address them (Jimison,
1998).
Dunn (2001) conducted a meta-analysis of 34 heterogeneous medical
studies of adult men and women who were cardiology, surgical, radiology,
cancer, and psychology patients. Dunn recommended that a variety of
educational interventions to improve understanding of informed consent should
be used to enhance the process, including video, multi-media and web-based
technologies. Dunn argued that further investigation is needed about
interventions to improve understanding because although the problem has been
well described, studies that actually test intervention methods have been limited.
Rosoff (1999) summarized the features of “prepackaged” informed
consent education programs such as those presented on DVD or CD-ROM. The
apparent benefits to the physician/researcher are that this method allows a lowtransaction cost transmission of fixed information. If accurate, it would provide all
of the relevant and necessary information with significantly less time and effort
than other (written) methods, and could document electronically the subject’s
comprehension. For the physician, the gains are in efficiency and standardized
information delivery. The apparent subject benefits are the receipt of a thorough
explanation with full details on risks and consequences. In addition, the subject is
able to access the material at their own speed without the pressure of the clock,
and discuss it with their family/spouse, but not the researchers, in the privacy of
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their home, instead of the physician’s office. If the technology permits, they can
self-test their comprehension and review topics that are not clear to them.
However, this technology eliminates the human interaction between the
patient/subject and physician/researcher and eliminates the opportunities for
spontaneous knowledge exchange with a professional that is the foundation of a
personal medical relationship. Rosoff (1999) acknowledged that the presentation
of information (in any format) does not assure knowledge and that it is very
difficult to objectively measure understanding when information is complex. Yet,
he asserts that comprehension is so important to autonomy and selfdetermination that any approach that comes closer to assuring comprehension
should be encouraged.
Current research on the informed consent process is slow in catching up
with the available technology offerings. Research studies focused on genetics
and proteomics, for example, have resulted in the creation of longer and more
complex informed consent documents. Medical researchers, focused on
innovative scientific methods, have not applied the parallel technological
innovations that are available to improve the informed consent process, nor has
there much effort spent in measuring the outcomes of varied informed consent
methods.
The Testosterone Trial at the University of Pennsylvania, School of
Medicine, is designed for men aged 65 and older. It has a complicated study
design; six separate informed consent documents (five abbreviated and one
comprehensive document); eligibility requirements in four separate areas;
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potential health risks; and a significant time burden. A risk assessment of these
factors served as an alert that the study may be difficult for potential subjects to
understand, resulting in a low rate of recruitment and a weak study initiation
phase. If this is the case, shortly after the study begins, the design and protocol
will require revision, resulting in delays, inefficiencies and cost overruns. In an
effort to mitigate this risk and the possible negative impact on the launch of the
study, I have developed an informed consent multimedia tool for this study to
serve as a supplement to the written form which I propose will add clarity to the
issues described above. The Research Informed Consent Multimedia Tutorial
(developed as a Powerpoint presentation) in Appendix A provides specific
information about the Testosterone Trial as well as the essential elements of
informed consent listed in Table 1.
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CHAPTER 3
HUMAN FACTORS
This clinical trial, designed to test the efficacy of testosterone, is currently
under review and is expected to begin in January 2009. Based on research by
Jimison (1998), Dunn (2001) and Rosoff (1999), there are several important
human factors to consider in developing the appropriate tool for use in this
research study including cognitive characteristics of older adults; learning styles
of individuals; knowledge assumptions; use of technology; and the physiciansubject relationship.
It is important to note that the participants in the Testosterone Trial are
research subjects who may or may not be patients of study investigators. As the
clinical settings will vary among the 18 research sites, it is possible that the
participants are not patients, and the investigators are researchers but not
healthcare providers to the participants. The terms subject and participant can be
used interchangeably; however, the term patient implies that a person is
participating in a health care relationship with the investigator/physician.
Another feature of this clinical trial is that it will be conducted as a doubleblind experiment. This means that participants are randomly assigned to the
treatment or placebo group and that neither the subject nor the researchers will
know which treatment a given subject is receiving. These methods are used to
reduce the unconscious and deliberate human influence on treatment
assignment and evaluation, and mimic the laboratory model of scientific
experimentation (Piantadosi, 1997).
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Cognitive Characteristics of Older Adults
Aging is associated with a gradual and progressive decline in many
aspects of cognitive function. The terms age-associated memory impairment
(AAMI) and late-life forgetfulness (LLF) are used to describe a condition that is
characterized by temporary memory lapses in otherwise healthy individuals
(Smith, 1991). The typical symptoms of AAMI include difficulty in recalling names
and words, and in associating a name with a face. In a memory study of 527
adults ages 55 to 98, Smith and Ivnik (1991) reported that age-related memory
changes vary depending on several factors including educational experience,
activity level and motivation. It is a challenge for clinicians to distinguish normal
age-related memory changes from early dementia, and there is lack of
agreement regarding the criteria for detecting the difference. Larabee and Crook
(1994) reported that the prevalence of AAMI among adults older than 50 ranges
from 39 to 85% and increases with age.
Sugarman, McCrory and Hubal (1998) performed a meta-analysis of 99
published empirical research measures on informed consent with older adults.
They found consistent evidence of impaired understanding of informed consent
information in older subjects and those with less formal education. Their
recommendations to improve the informed consent process included
simplification of text, and novel formats and tools that promote interaction to
enhance comprehension. Recognizing these natural, complex outcomes of
aging, it is prudent to assume that many of the men who read the Testosterone
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Trial informed consent document will have some difficulty remembering the
details described in its 17 pages (see Appendix B).
Recall alone does not imply understanding; indeed, there is a lack of
clarity in defining understanding. The complex cognitive processes involved in
reading, attention and memory are called by several different terms such as
understanding, knowledge, comprehension, and recall that do not mean quite the
same thing but are often used interchangeably. Dunn (2001) reported a metaanalysis of 34 clinical studies which included people of all ages, in which
problems with understanding the research consent form were widely reported.
These included lack of awareness about being a subject in a research study,
poor understanding of placebo and randomization, confusion about risks and
benefits, lack of awareness of the ability to withdraw from the study without
consequence, and therapeutic misconception which is the belief that treatment
decisions are being made solely for the individual’s benefit. The problem of
therapeutic misconception occurs more often when a subject’s only role is as a
participant in a research study, compared to the subject who is also a patient in a
healthcare relationship. There are studies that acknowledge the difficulty in
measuring memory for presented information versus comprehension in
assessing understanding of informed consent information, but the number of
studies that test methods to improve the process has been limited.
Learning Styles of Individuals
Adults bring many years of learning experiences with them to any new
learning situation, integrating new learning with prior learning. In order to meet
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the learning needs of adults the content of any material must be relevant; if
adults see the usefulness of the material presented, their motivation to learn
increases. Adults also tend to prefer active learning that is related to their real-life
situations as well as self-directed learning (Disabilities, Opportunities,
Internetworking and Technology, Adult Learning, 2006).
This is relevant because participation in this research is voluntary; only
those men who are eligible and motivated by the potential for improvement in the
four research realms will reach this stage of the enrollment process. I believe that
this multimedia tutorial will enhance the informed consent process for the adult
learners in this study as it allows self-directed learning, in which the learner has
some control over the pace and content of the program.
The men who volunteer to participate in the Testosterone Trial will be a
diverse group of 1200 older men varying in race, level of education and
geographic location. In developing a multimedia tool, it is important to
acknowledge that they are also individuals who will have different learning styles.
It has been reported that educational level is directly correlated to level of
understanding of informed consent, which is one of the reasons that the
readability of informed consent documents has been established at the eighth
grade reading level. But this one parameter does not consider the many other
aspects of taking in information that are relevant.
VARK (Visual, Aural, Read/Write, Kinesthetic), developed by Flemming
(1987), is one of the many dimensions of learning preferences, and is focused on
the way that an individual takes information in and puts information out in a
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learning context. VARK is a mechanism for profiling individual learning
preferences, but not necessarily strengths. There are some consistent reports of
matches between VARK results and perceived preferences; however, statistical
data are not yet available to prove the validity and reliability of VARK.
In order to reach every learner, media should be constructed to address
the VARK preferences for obtaining knowledge of the audience. The VARK data
indicate that men have more kinesthetic responses than women but overall
learners are distributed across the four domains. There are limitations to the
kinesthetic learning experiences that the multimedia tool can provide; however,
the tutorial will include visual, aural, and read/write components to address those
learning aspects. (See Appendix C, Multimedia Tool Development Proposal).
Knowledge Assumptions
Recruitment techniques in the Testosterone Trial will vary widely. One
technique will use national media, local media and mass mailings targeted at
older men who will be asked to contact the research center if they are interested
in a testosterone research study. This subject generated contact implies only that
respondents are willing to learn more information. No further assumptions should
be made about what respondents know about research or testosterone. Holden
(2005) reported a study of men aged 40-79, wherein 27% of respondents were
not familiar with the term testosterone; more men (40% of respondents) in the
older age group (60-79) indicated unfamiliarity with the term.
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Pilot Study
I conducted a pilot study of structured individual interviews with eight men
who appeared to be candidates for the Testosterone Trial study. The interview
instrument is included in Appendix D. This group was a convenient sample of
friends and family members; therefore, the results should be considered
exploratory data only. The instrument and process warrant further evaluation and
refinement. I recruited eight White/Caucasian men ranging in age from 65-85
years (Mean = 73.7 years). Educationally, 3 (37.5%) attended or graduated from
college; 5 (62.5%) had a high school education or less (see Table 2). A complete
summary is included in Appendix E.
Table 2. Pilot Study Participant Demographic Characteristics (n=8)
Education
7th to 12th grade, no high school diploma
High school graduate or equivalent (e.g. GED)
Some college education, but not completed degree
College graduate

Number (%)
1 (12.5%)
4 (50%)
1 (12.5%)
2 (25%)

Subjects and Methodology
Each man read the consent form to himself after which I conducted an
interview with him and collected information about his reaction to several
sections of the consent form, including understanding the four trials, the
Interactive Voice Response system, placebo, and risks, as well as willingness to
discuss this study with his spouse/significant other/family member and physician,
and capacity to use other media to explain the clinical trial. The interviews were
conducted at the respondent’s homes between February 12 and March 10, 2008.
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The respondents had many shared opinions. The comments that I
recorded during the interviews provided much more information about the
preconceived notions, knowledge and understanding that the interviewees had,
than the dichotomous responses to the questions.
I had extensive discussions with five of eight men about use of a placebo.
None of the men interviewed had ever participated in a research study. They
stated that they understood the difference between the active and placebo
medications used in the study, but they also said that they would not want to be
in a study where they might use a placebo instead of testosterone gel. These
men learned about testosterone primarily from sports news. They knew that it
was available by prescription from a physician and felt that there would be no
need to participate in a trial if they were inclined to use testosterone. (I explained
that testosterone should only be used if the level of that hormone is significantly
low. Also, I explained about the importance of monitoring adverse effects.) These
discussions suggest that some men may have had trouble understanding and/or
accepting the value in using a placebo in this study and that it is important to
include a clear explanation of the placebo in the tutorial and to evaluate the level
of understanding.
Addressing the ethical concerns of the placebo controlled trial has been
controversial and debated in the medical literature for many years. Opponents
claim that it is unethical in that it places scientific rigor over the needs of people.
Proponents explain that regulatory oversight of research and the informed
consent process ensure that its use is ethical, provided participants understand
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the rationale and risks if assigned to the placebo condition (Emanuel, 2001). It is
probably naive to assume that regulatory oversight in academic medical centers,
local clinics, doctor’s offices and wherever research is conducted, can provide
the needed rigor and standardization to protect research subjects. Bok (1978)
warned that the use of placebos is not innocuous, that the safeguards against
this practice are few or nonexistent both because it is secretive in nature and
because it is condoned but rarely discussed in the medical literature and that it
undermines the medical relationship.
The men in this sample had a wide range of accurate and inaccurate
information about prostate cancer. Their comments suggest that the experiences
of individual men they knew seemed to influence their perceptions more than
information they heard from doctors. All of the men (100%) expressed concern
about prostate cancer; 75% were not clear about the effect of testosterone on
their risk of prostate cancer. I discussed “occult” prostate cancer with all of these
men and found that half of the men understood the concept of occult prostate
cancer but that the term “occult” in this context created confusion. This is the kind
of practical information that helped me write the risk section of the tutorial, which
I found to be the most difficult.
Use of Technology
It would be a mistake to assume that the men in the testosterone trial will
be able to easily use a web-based tool or a DVD to view the tutorial at home.
Three major studies conducted between 2003 and 2005 revealed that 25 - 41%
of adults aged 65 and older use the Internet (Doing the Math, Older Adults
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Online, 2005). In this sample of eight men, five (63%) did not own a computer
and 75% did not feel comfortable accessing the tutorial from a website. This is
important information to know about potential participants. It suggests that the
tutorial may be viewed primarily at the research clinic during the baseline visit,
under the guidance of the research staff; however, it must also be portable so
that men who are facile with technology can take the tutorial home to read and
answer the questions. The method must be uncomplicated and reliable however
subjects prefer to access the tutorial. A brief training or practice session should
precede distribution of the DVD for home use to ensure that users have the
ability to access the media and know how to use the features of the tool.
This also suggests that one of the potential benefits of the tutorial, the
transmission of information with less time and effort by the research staff, may
not be realized. A common research practice used to gain efficiency in the
informed consent process is to distribute the document and other educational
information, such as a study fact sheet, to the subject even before it has been
determined that he is eligible. In this study, a man who has completed the
screening visit could be given the informed consent document and tutorial to take
home, even though his eligibility status has not yet been determined. When it is
verified (by confirming lab data) that a man is eligible, he can be contacted and
instructed to read the form and complete the tutorial at home, before the next
research clinic visit. There are potentially negative consequences to this
approach. If a man has questions, he has no one to ask and if he encounters
technological trouble using the tutorial he may become frustrated and abandon
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the tutorial. In addition, the introduction of technology into the informed consent
process may dilute the compassionate, human exchange that forms the core of
the medical relationship (Rosoff, 1999). Therefore, it could be risky to rely on
technology to meet the needs of subjects during the informed consent process,
unless the research team continues to invest the time and energy needed to
thoroughly discuss the research and address all of an individual’s concerns.
Ultimately it is the combination of the technology and the human elements that
will determine how well the tutorial will be received.
Physician-Subject Relationship
The current practice of obtaining informed consent relies on the
physician/subject relationship and is based on the assumption that this activity is
worthwhile to the physician and the subject (Rosoff, 1999). In introducing
technology to educate subjects about research, it is important to consider how it
could diminish the important bonding process that takes place when a doctor and
subject engage in a meaningful conversation about their health or quality of life. It
is essential that human interaction is not reduced because a tutorial or other
electronic aid is used. In obtaining informed consent, physicians must be
committed to meeting a subject’s emotional needs in addition to their
informational needs.
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CHAPTER 4
METHODOLOGY
Three subject matter experts contributed to the development of materials
for the tutorial. The design team included Peter J. Snyder, M.D., Principal
Investigator of the Testosterone Trial. Dr. Snyder is an endocrinologist at the
University of Pennsylvania, School of Medicine, and has conducted testosterone
clinical research for over 30 years. Dr. Snyder was the subject matter expert for
the medical content presented in the tutorial. Gregg Fromell, M.D., Director of
the Office of Human Research (OHR), at the University of Pennsylvania, School
of Medicine, provided expertise on research education, training and compliance.
Dr. Fromell leads the initiative to develop standard tools, methods and teaching
materials for the Penn OHR and has extensive experience in evaluating informed
consent documents. He was the subject matter expert on the essential elements
of informed consent, readability and format of the tutorial. Barry Dornfeld, Ph.D.,
is an Educational Media Consultant and co-leader of the Center for Applied
Research (CFAR) Action Learning initiative. Dr. Dornfeld provided expertise in
development of content and organization of biomedical knowledge and served as
a reviewer of the entire multimedia tool.
The initial project to develop an informed consent video was modified to a
multimedia tutorial to reduce delivery time and facilitate anticipated revisions to
the project following review by the research network investigators. The design
team focused on developing a multimedia tutorial that would enhance
understanding of the information presented during the informed consent process

V1.20080627

27
for the subjects; meet established institutional guidelines for research; be
appropriate to subjects; be interesting and attractive to users; be portable as well
as accessible from the internet.
Print media is inexpensive, convenient and familiar; however, it is not
interactive and often requires higher literacy levels of users. Advances in
computer technology have enabled the construction of multimedia learning tools
from online libraries of static and dynamic images, but it is difficult to know what
changes for the learner when you add pictures to words (Elloumi, 2008). Mayer
(2001) defined multimedia as the presentation of material using words (printed
and spoken text) and pictures (static graphics and video). In proposing to use a
multimedia tool in addition to text, there are several adjustments to consider.
The tutorial structure was based on the model designed by the National
Library of Medicine (NLM) which provides a comprehensive program of
authoritative health information tools (Medline Plus, 2008). The content is in
alignment with but not identical to the informed consent document as the tutorial
is meant to work in conjunction with the document. The pilot test results helped
shape the content significantly in terms of emphasis on explaining the four trials,
use of placebo, and risks. It also suggested that some words were confusing so
we avoided terms that require specialized knowledge. The tutorial was developed
in parallel with the interviews as well as continuous review by the design team. It
was reviewed at regular intervals by Dr. Snyder, Dr. Fromell and my colleagues
in the Clinical Research Computing Unit. Table 3 identifies the content of the
tutorial modules.
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Table 3. Testosterone Trial Tutorial Table of Contents
Modules
Introduction
Participating in the Trial
4 Testosterone Trials in 1
Tests and Procedures
Risks and Benefits
More Important Information
Summary

Number of Slides
18
11
17
11
18
11
8

The tutorial that accompanies the Testosterone Trial informed consent
document was designed to enhance information in order to facilitate balanced
decision-making. Based on data from Rosoff (1999), it seemed important to
simplify the content, permit self-paced learning and support interactive learning.
We wanted the users of this tutorial to make sense of what they see and hear.
The output of responses to the “Check Your Understanding” questions is
provided to guide the research team about the topics that should be reviewed or
reinforced with the subject. Figure 1 presents two questions from the Risks and
Benefits module.
Figure 1. Check Your Understanding about Testosterone Risks
Check Your Understanding
Using testosterone will cause you to have sleep apnea.

True
False

You will have a prostate biopsy at the end of the study.

True
False

I avoided focusing on the technology over the content and have included
features that are functional without embellishments. The tutorial was developed
to incorporate brief video streams to present information from men who resemble
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the subjects in the study, and from physicians who convey concern for the health
and safety of participants in the study. It is important that these images are
appropriate as well as interesting to attract the subject’s attention.
The tutorial will be implemented and accessed from a secure Internet
website; it will also be portable to permit access from a stand-alone computer
system, via DVD. It will be introduced with a brief explanation of its purpose
which is to provide information about the study, not specific medical advice. It will
explain that the video and pictures have been included to enhance the text. The
‘Check Your Understanding’ questions are asked to verify that the subjects
understand the material as presented at that time. By documenting responses
within the program, the tutorial will provide those administering the informed
consent process the opportunity to review content that is not clear by examining
the subject’s responses, thereby verifying understanding. This method of
assessment does not address the problem of understanding versus recall, nor
does this tutorial distinguish between short and long term recall. However, it has
the potential to enhance satisfaction with the informed consent process, provide
added value to potential subjects and may serve to reinforce learning by
repeating information that is provided to them in the informed consent document
in a media that is familiar, accessible and clear (Jimison, 1998).
The benefits of the tutorial are that it provides the same critical information
to all subjects and documents the provision of it for legal purposes. In addition, if
presented to subjects during the baseline visit, the tutorial is a prudent use of the
subject’s waiting time, which is a concern in this study where this first research
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visit can last up to four hours. This is also a risk as the use of this program has
the potential to diminish an aspect of relationship building and trust that evolves
before and during the informed consent process. Rosoff (1999) noted that the
personal bond between the physician and subject/patient, which has been
considered an essential element of the therapeutic relationship, may be
weakened by the use of computerized information disclosure devices. As
subjects/patients become better educated, the nature of the relationship
becomes more collaborative; however, there is a tendency when a transaction is
routinized and reduced to a ritual, for the ritual to stifle dynamic human
interaction. It is important that this is not overlooked because a subject may
begin, but may not continue to participate in a study that offers no direct benefit
to him, unless there are some interpersonal and/or social reasons for doing so.
In trying to incorporate all of these elements into the tutorial, differences of
opinion among the design team emerged. Dr. Dornfeld suggested that repetition
is useful in conveying such specific information whereas Dr. Snyder expressed
concern that the tutorial was too long and repetitive. Everyone was interested in
selecting the photos and graphics. As the tutorial is graphics based, it was
believed to be important to include the appropriate representation of men and
health care providers in the pictures and video clips. This meant including men in
the entire age range, of all races, professions and lifestyles. (The present photos
are those that were freely available and will be replaced before the tutorial is
produced.) The graphic elements could add impact by streaming video of a
physician explaining the complex aspects of the study such as the study design,
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placebo and risks. Providing a message from a familiar authority figure was
believed to enhance the credibility of the content. The video clips could also
include men as subjects demonstrating a procedure such as stair climbing, as
subjects have reported that they find such clips useful (Agre, 2003). Ultimately
the richness of the media will be balanced by the cost.
It is worth noting that not only will the subject matter experts have different
reactions to the tutorial but that the users will also have diverse opinions about
the content. The original objective was to develop a tutorial that would be more
informative for participants than the traditional text method; as such, it will be
important to include a step in the development process that incorporates the
feedback of these stakeholders in the design process.
Dr. Dornfeld and I discussed the “Check Your Understanding” sections
and how they can be most useful, given the static nature of the media and the 8th
grade reading level requirement. The Flesch Kincaid Grade Level score of the
tutorial is 7.6, which is equivalent to a reading level between 7th and 8th grade.
The Flesch Kincaid Grade Level Score is a measure based on the number of
words per sentence and the number of syllables per word (Flesch Kincaid
Readability Score, 2008). Initially, the tutorial had two questions per module as I
tried to avoid asking questions in which the responses were a simple return of
facts just learned. Dr. Dornfeld urged me to examine what I was trying to achieve
in asking these questions; is it important for subjects to answer them correctly or
to serve as an indicator of level of understanding? As the long-term objective was
to test this method for improving understanding of informed consent rather than
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to rely on the paper document only, the responses should serve as an indicator
of understanding associated with each module. He pointed out that many
important aspects of the study were presented in each module and that this is the
only opportunity in the process to evaluate what a subject knows at this point in
time. He suggested that I develop additional questions for each module as they
can serve, at a minimum, as a way to demonstrate that a subject has paid
attention. Additional post-test questions could be developed and administered at
a subsequent research visit, one or three months later, for example, that could
serve as measures of information retention. Dr. Snyder was concerned about
asking so many questions of subjects during the tutorial and thought that this
could be an obstacle to some subjects. We agreed to include all of the questions
and to conduct a formal pilot test and focus group to learn more about each
subject’s reaction to the number and content of the questions. Dr. Dornfeld also
recommended that the tutorial include guidelines with the output that would direct
the person administering the informed consent process to review the topic areas
that are not clear to the user. Early evaluation (during pilot testing of the tutorial)
of the number and content of incorrect responses will help to revise the tutorial to
meet the needs of the users.
As an endocrinologist, Dr. Snyder focused on presenting the medical
content clearly and succinctly. He concentrated on the prostate cancer risks of
the study as they are the most difficult to convey because they assume some
knowledge about prostate cancer and its risk factors, non-specific symptoms,
and the approaches to treatment that the medical community endorses (The
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University of Texas, M.D. Anderson Cancer Center, 2008). The pilot data indicate
that these issues are cloaked in some level of anxiety by men. The safety
monitoring for prostate cancer that is included in the Testosterone Trial is more
vigilant and conservative than is the standard medical practice, which is a fact
that may not be apparent to subjects. To explain these distinctions may require
providing additional information about prostate cancer; however, this may
heighten fears about prostate cancer that may or may not be warranted. This is a
complex issue that the investigators have been struggling with at every phase of
the proposal and is under discussion with the sponsor and the scientific review
committee. Yet, our obligation in the informed consent process is to fully disclose
all risks to the subject and this may require providing supplemental information.
Figure 2 depicts the prostate cancer risk section of the tutorial.
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Figure 2. Risks and Benefits Module: Prostate Cancer Risk

Prostate cancer
There could be small areas of cancer in the
prostate that are not harmful and are not
causing a health problem to you now. Using
testosterone could change these small prostate
cancers that are not harmful, into harmful ones.
Presently, there is not enough information to
know for certain about the effects of taking
testosterone on prostate cancer.
You will have rectal exams to check your
prostate, and blood tests to learn your PSA
result, which is the prostate cancer blood test.
You will be asked questions about your prostate
health and medical history.
Your prostate and the risk of developing
prostate cancer will be monitored closely over
the course of the study. Regular screening such
as the kind you will receive in this study, helps
detect prostate cancer in its early stages.

Dr. Fromell focused on the essential elements of the informed consent
document as they are represented in the tutorial. Because of several recent
instances of loss of research data in NIH and Veteran’s Administration studies,
there is heightened interest by universities and sponsors about issues of data
privacy and the disclosure of Protected Health Information (PHI), the individually
identifiable health information such as name, address, medical history and
medical record number (HIPAA Privacy Rule, 2007). All informed consent
documents and any information provided to subjects as informed consent tools
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such as this tutorial, must describe how these data will be protected, how they
may be used and to whom they may be disclosed. The institution must not use
vague statements such as “every effort will be made to protect your personal
information;” rather we must strive to be as specific as possible in describing how
confidential data will be protected. This can be confusing and worrisome to
subjects. Figure 3 depicts the section of the tutorial that describes protection of
confidential information.
Figure 3. Risks and Benefits Module: Confidential Health Information
Will confidential health information be collected as part of this study?

Some private information about your health will be collected like your medical history,
and your answers to questions about your physical function, sexual function, and
other questionnaires.
All information (including blood samples) collected in this study is kept strictly private
by using study code numbers to collect information instead of names.
This code number will be on the blood samples, questionnaires and in the
computer that saves your responses.
Your contact information will be locked securely in files at the
research clinic and used only by the staff to contact you.
The information collected in the study is saved in a highly secure computer system.
Only those people who are working to analyze the information will be able to view it.
Authorized study representatives may review and copy data collected from
this study and your medical records. Your name will never appear in
any articles that are published of the results from this research.

In order to advance this tool to the implementation stage, Dr. Dornfeld
recommended that I write a development proposal to accompany the tutorial that
describes the scope of work for the production phase. This was completed and is
presented in Appendix C, Multimedia Tool Development Proposal. It includes
information about who will be responsible for the content, description and
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expectations of the incorporated technology, and the review and approval
process. He urged me that the production process should not begin until such
information is written and clarified.
The content and format of the Testosterone Trial tutorial will remain stable
for a brief time. The next phase will be review and revision by a larger group of
physicians and researchers from among the 18 Testosterone Trial Research
Network clinical sites who will evaluate it based on their institutional requirements
and the needs of their local study populations. In order to evaluate this aspect of
the tutorial it will be pilot tested in several research centers. This is an important
step as the clinical sites differ widely, from an upper-middle class San Diego,
California suburb to downtown Birmingham, Alabama. The tutorial will ultimately
be reviewed by the Institutional Review Board of each participating medical
center.

V1.20080627

37
CHAPTER 5
CONCLUSION
The informed consent process is an imperfect one as it is dependent on
many variable human factors. Yet, it is a pivotal element of clinical research;
without human volunteers, advances in medicine would be very limited and much
riskier. Research practitioners have a responsibility to ensure that participation in
research is informed and voluntary. This implies that we should strive to improve
the effectiveness of informed consent methods.
The scientific literature consistently reveals evidence of impaired
understanding of informed consent information in older subjects and those with
less formal education (Sugarman, McCrory, Hubal, 1998). This is an important
consideration for the Testosterone Trial. The men in the trial will be 65 years and
may have some health problems and age-associated memory impairment. The
Testosterone Trial informed consent document is lengthy (17 pages), yet it still
may not be adequately explaining important issues such as prostate cancer risk.
It is difficult to reduce complex medical problems and research procedures to a
few written paragraphs, while simultaneously acknowledging that there are still
many aspects of testosterone use and risk that are unknown.
What can be expected of people to know about the Testosterone Trial in
order to make an informed choice, and how should it be measured? For informed
consent to be meaningful, research subjects deserve to have all of their
informational needs regarding a proposed intervention met. A growing body of
literature shows that decision aids such as multimedia tools can influence
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subjects’ decisions and improve satisfaction with research participation, and it is
almost certain that as technology weaves its way into all aspects of daily living
that such tools are here to stay (Rosoff, 1999).
The next step to developing and implementing this tutorial is to present it
to the research network investigators for final review and revision of content,
pictures and graphics. After the final product is reviewed and approved by the
Institutional Review Board at the University of Pennsylvania, it will likely be
developed as a multimedia tool. During the pilot phase of the trial, I propose to
conduct a pilot study of the informed consent process. The design will be a threearmed study to measure differences in subject reactions among those who read
the paper informed consent document only; those who use the multimedia tool
only; and those who use the paper document and multimedia tool. The study will
include pre- and post-testing phases and follow-up testing at 3 and 12 months.
The tests will aim to discern differences between the three groups in terms of
ability to answer specific questions about the research purpose and risks as well
to accurately describe the study. It may be feasible to conduct focus groups with
subjects who complete the study to discuss the reality of study participation
compared to the initial description presented during the informed consent
process.
There is little research about the research process. As a result,
established methods for conducting a study of this type are not available. I will
examine the preliminary data and evaluate the process early during the pilot
study to further develop and refine the methods. I will seek collaboration with the
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Penn Office of Human Research, as they are the subject matter experts and
thought leaders in the development of informed consent materials. I expect that
this study will provide information about whether understanding of informed
consent can be improved with educational interventions.
Future research in this area could assess the optimum length and content
of multimedia tools; feasibility and acceptability of this media; and legal and
ethical implications of using multimedia instead of written text for obtaining
informed consent. The publication and presentation of the results will inform
researchers about the utility and benefits of advanced technology approaches to
the informed consent process. The organizational changes that would have to
occur in order for this process to gain acceptance in the medical research
community will be formidable. It will require an extensive communication plan to
show that such a process change is advantageous to researchers as well as an
improvement for subjects.
As clinical trials continue to evolve, becoming increasingly large,
decentralized and global, it is important to maintain the fundamental human
principals of autonomy and self-determination. As the shapers of medical care
and public health, researchers are obligated to strive to improve the human
aspects of the medical research process as well as the scientific ones, and to
seek innovative and informative ways to benefit the citizens who participate.
Gaining truly informed consent should be the objective of the process, not merely
meeting the letter of the law.
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Slide 1
Testosterone Trial
Research Informed Consent
Education Program
Denise Cifelli
Capstone 705
May 2, 2008

Slide 2

Instructions

Slide 3

Table of Contents
•
•
•
•
•
•
•

Slide 4

Introduction
Participating in the Trial
4 Testosterone Trials in 1
Tests and Procedures
Risks and Benefits
More Important Information
Summary

Introduction
This tutorial includes information about the
Testosterone Trial, not specific medical
advice.
The pictures have been included to
improve your understanding.
If you have questions, please write them
down and ask the doctor or someone from
the research team.
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NOTE: This slide will explain the functionality that
is incorporated into the tutorial and will describe
the features (using audio and video) that are
included in the modules such as the table of
contents, navigation buttons, mouse-over
information and the Check Your Understanding
sections.
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Slide 5
Welcome to this education program
about the Testosterone Trial
Research Study.
The Testosterone Trial is sponsored
by the National Institutes of Health
and Solvay Pharmaceuticals.

Slide 6
This program will explain the Testosterone
Trial to you so that you can decide if you
are interested in taking part.
The Testosterone Trial is being conducted
by doctors and nurses at your health
center and around the United States to
study how using testosterone affects
men’s health.

Slide 7
The information in this
program accompanies the
consent form that you were
given to read.
This education program
was made to provide clear
explanations of the study
details to help you better
understand the study and
make an informed choice
about participating.

Slide 8
Experienced doctors,
nurses and members
of their research
teams will conduct
this research study at
18 medical centers in
the United States.

V1.20080627

45

Testosterone Trial Informed Consent Education Program - Appendix A

Slide 9

Testosterone Trial Network Map

Seattle, WA
Portland, OR
Palo Alto, CA
Los Angeles, CA
San Diego, CA

Minneapolis, MN
Chicago, IL
Pittsburgh, PA
Birmingham, AL
Houston, TX
Galveston, TX

Slide 10
This is a research
study about men, age
65 and older, using
testosterone.
Your regular doctor
will continue to work
with you to manage
your medical care.

Slide 11
As people age, they change in
many ways which are part of
the normal aging process.
They may have difficulty
walking, less interest in sex,
difficulty remembering and
less energy.
When men get older, the
amount of testosterone, the
main male hormone, gets
lower. It is possible that low
testosterone could be a cause
of these changes.

Slide 12
The goal of this study is to
find out if older men who
take testosterone will have
improvement in walking,
be more interested in sex,
improvement in memory
and an improved energy
level.
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Boston, MA
New Haven, CT
Hartford, CT
New York City, NY
Baltimore, MD
Washington, DC
Gainesville, FL
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Audio - These are the 18 medical centers that are
part of this research study.
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Slide 13
The 4 areas of
research in this study
are….
• Physical Function
• Sexual Function
• Memory
• Energy

Slide 14

Physical
…is focused on
walking, climbing
stairs, moving
around safely and
doing daily
activities.

Slide 15

Sexual
…is focused on your

interest in sex and
your ability to have
sex, as well as
your thoughts and
feelings about sex.

Slide 16

Memory
…is focused on your
memory for
information that your
hear, information
that you read to
yourself, and other
tests of your mental
ability.
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Energy
…is focused
feelings of
tiredness, energy
level, moods and
emotional states.

Slide 18

Slide 19

Check Your Understanding
The study will be conducted in
men under age 65.

True
False

When men get older, their
testosterone level decreases.

True
False

Check Your Understanding
This is a study of how
testosterone affects your…..
(Choose one)
a. Walking, sexual interest,
reading ability, energy
b. Walking, sexual interest,
memory, relationships
c. Walking, sexual interest,
memory, energy
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Check your
answer
here.

a. □
b. □
c. □

A mouse-over feature will be used in the
checkboxes to explain which answers are correct
and incorrect, including a brief explanation.
Check Your Understanding Statement:
The study will be conducted in men under age 65.
True. Incorrect. The study will include men who
are 65 and older.
False. Correct. The study will include men who are
65 and older.
Check Your Understanding Statement:
When men get older, their testosterone level
decreases.
True. Correct. As men age their testosterone level
decreases over time.
False. Incorrect. As men age their testosterone
level decreases over time.
Check Your Understanding Statement:
This is a study of how testosterone affects your....
a. Incorrect. The study will look at the effect of
testosterone on walking, sexual interest, memory,
energy
b. Incorrect. The study will look at the effect of
testosterone on walking, sexual interest, memory,
energy
c. Correct.
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Slide 20

Participating in the Trial

Slide 21

What will happen in this study?
During this research study, men will take
testosterone for 1 year. Men will
participate in research visits by answering
questionnaires and performing tests.
When the study is over, doctors will know
a great deal more about the effects of
testosterone, and if it improves men’s
health and well-being.

Slide 22

Voluntary Participation
Taking part in this research
study is voluntary. You do
not have to take part in it if
you do not want to.
If you do take part, you can
leave at any time.
If you decide not to take
part, your medical care will
not be affected in any way.

Slide 23

Qualifying to be in the study is
based on ….
•
•
•
•
•
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Age - 65 years or older
Testosterone level between 100 and 250
Symptoms you report
Your medical history
Answers to questionnaires
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Why are you being asked to take part
in this study?
You are being asked to take part in this
study because you are 65 or older and
your testosterone level is low. This
information was found when your blood
was tested at the previous visits.
The questions that you answered show
that you have some of the signs and
symptoms of aging that low testosterone
might cause.
You have been asked to read this consent
form and consider being in the study
because you seem to be a good match for
the study.

Slide 25

What is the purpose of this
research study?
Testosterone is a hormone
produced by your body.
The amount of this hormone
decreases with age.
The main goal of this study is to
find out if using testosterone
improves walking, sexual
interest and function, memory,
and energy in men your age.

Slide 26

How long will you be in this
research study?
If you decide to take part, you will be in the study for 2
years.
In the 1st year, you will take testosterone or a placebo.
In the 2nd year, you will not take testosterone, but will
continue to be in the study.

Year 1
Testosterone Treatment Phase
(12 months)

Year 2
Follow-up Phase
(12 months)

Slide 27
During the 1st year, you will come to the research clinic
for 7 visits and you will be called by the research team
6 times for information. The chart below shows
when those visits will happen.
Year 1
Testosterone Treatment Phase
(In Months)
0*

1

2

3

4

5

6

7

8

9

10

11

12

C

C

C

C

P

P

C

P

P

C

P

P

C

*This visit is called the Baseline Visit.
C = Research Clinic visit in person; P = Phone contact
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During the 2nd year, you will come to the research
clinic once and answer questions by

↓

telephone once.

Year 2
Followup
Phase

Year 1
Testosterone Treatment Phase
(In Months)

0

1

2

3

4

5

6

7

8

9

10

11

12

18

24

C

C

C

C

P

P

C

P

P

C

P

P

C

C

P

C = Research Clinic visit in person; P = Phone contact
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Check Your Understanding
If you take part in the
study, you have to stay
in it for 2 years.

True
False

Accurately reporting
your medical history is
important to the study.

True
False

Check Your Understanding
Testosterone is a
male hormone that
decreases with age.

True
False

You are being
asked to participate
in this study for …

6 months
1 year
2 years

Check Your Understanding Statement:
If you take part in the study, you have to stay in it
for 2 years.
True. Incorrect. If you start the study and do not
want to finish it, you may stop when you want.
False. Correct. If you start the study and do not
want to finish it, you may stop when you want.
Check Your Understanding Statement:
Accurately reporting your medical history is
important to the study.
True. Correct. It is important to provide accurate
information about your past and present health
conditions.
False. Incorrect. It is important to provide accurate
information about your past and present health
conditions.
Check Your Understanding Statement:
Testosterone is a male hormone that decreases
with age.
True. Correct. As men age it is normal for
testosterone, the main male hormone, to
decrease.
False. Incorrect. As men age it is normal for
testosterone, the main male hormone, to
decrease.
Check Your Understanding Statement:
You are being asked to participate in this study for
6 months. Incorrect. You will participate in the
study for a total of 2 years.
1 year. Incorrect. You will take testostereone for 1
year but will participate in the study for a total of 2
years.
2 years. Correct.
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4 Testosterone Trials in 1

Slide 32

What is involved in this research
study?
This study involves using testosterone or a
placebo for one year in the form of a gel applied
to the skin. The tests that you take and
questions that you answer will show what
changes, if any, happen.
The questionnaires that you answered were
done to find out which of the 4 areas of study
match what you reported about your health.

Slide 33
You could be in one or
more of the 4 separate
studies, called trials.
For the trials in which you
qualify, you will take part
in those that you choose.
The four trials are focused
on:
–
–
–
–

Slide 34

Physical Function
Sexual Function
Memory
Energy

Physical Function
…..is about how well you
get around physically
in terms of walking
and moving around.
This trial measures
walking speed, stair
climbing, and asks
questions about
physical activity.
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Sexual Function
…..is about your interest in
sex and your ability to
have sex. This trial asks
for information about your
sexual function and
thoughts.
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Memory
…..measures memory
of information you
have heard, written
information and
several other tests of
your mental ability
such as your
memory of designs
and drawings.

Slide 37

Energy
…..asks about your
energy level, moods,
depression and
quality of life.

Slide 38

What does study assignment mean?
You will be in one of two
groups. One group will be
given testosterone gel. The
other group will be given a
matching placebo gel, which
does not contain testosterone.
Study assignment means being
put in one group or the other.
A computer program will select
the group that you are in.
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Placebo
A placebo is a substance that is
made without the active ingredient,
but looks like the “real thing.” The
testosterone and placebo gels will
be in identical pump bottles. The 2
gels will look, feel and smell exactly
the same.
No one who is working on the
study (the doctors, nurses, staff or
you) will know which group you are
in. This is done so that everyone is
treated the same, without different
expectations of how you might
answer questions or perform in
tests.

Slide 40

How do you take testosterone?
You will apply a specific
amount of testosterone gel
directly on your chest,
stomach or upper arms once
a day, every day for a year.
You will be shown how to do
this so that you use the
correct dose of gel.

Slide 41
The amount of gel
that you get from the
pump bottle will be
prescribed. This is the
dose of testosterone
that you will be using.
You should not use
more or less than this
dose.

Slide 42
It is important to wash your
hands after putting on the gel.
You must then let the gel dry
and cover up your chest with
a shirt before having any
physical contact.
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Testosterone

Placebo
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Slide 43
Blood will be drawn to
check your testosterone
level each time you
come to a research
clinic visit.
If a dose change is
needed, you will be told
exactly what to do.

Slide 44

Slide 45

Check Your Understanding
It does not matter how much
gel is used when applying
testosterone gel.

True
False

Blood will be drawn at each
research clinic visit to check
the testosterone level.

True
False

Check Your Understanding
Study assignment means
that….
(Choose one.)

a. A computer will calculate
your testosterone level.
b. You will be put into one of
two groups.
c. There will be additional
reading to do for the study.
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Check your
answer
here.

a. □
b. □
c. □

Check Your Understanding Statement:
It does not matter how much gel is used when
applying testosterone gel.
True. Incorrect. The amount of gel applied to the
skin is the prescribed dose of testosterone that
should be used.
False. Correct. The amount of gel applied to the
skin is the prescribed dose of testosterone that
should be used.
Check Your Understanding Statement:
Blood will be drawn at each research clinic visit to
check the testosterone level.
True. Correct. Blood will be drawn at each visit to
check testosterone level as well as several other
tests.
False. Incorrect. Blood will be drawn at each visit
to check testosterone level as well as several
other tests.
Check Your Understanding Statement:
Study assignment means that….
a. Incorrect. Study assignment means that you will
be put into one of two groups.
b. Correct.
c. Incorrect. Study assignment means that you will
be put into one of two groups.
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Check Your Understanding
The study doctors and nurses will
choose which group you are
assigned to.

True
False

After applying the gel, you should
wash your hands and cover the
skin so that others do not touch
the gel.

True
False

Check Your Understanding
In this study, the placebo is…
(Choose one.)

a. A pill
b. A gel with a different
medication than
testosterone
c. A gel that will seem identical
to testosterone gel but will
not have testosterone in it
d. A device

Check your
answer here.
a. □
b. □
c. □
d. □
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Tests and Procedures
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Check Your Understanding Statement:
The study doctors and nurses will choose which
group you are assigned to.
True. Incorrect. The group that you are in
(testosterone or placebo) will not be chosen by
anyone in the research study. A computer will
make the study assignment.
False. Correct. The group that you are in
(testosterone or placebo) will not be chosen by
anyone in the research study. A computer will
make the study assignment.
Check Your Understanding Statement:
After applying the gel, you should wash your
hands and cover the skin so that others do not
touch the gel.
True. Correct. Even after the gel dries on your
skin, you must wash your hands and cover the
skin so that others do not come into contact with
the testosterone on your skin.
False. Incorrect. Even after the gel dries on your
skin, you must wash your hands and cover the
skin so that others do not come into contact with
the testosterone on your skin.
Check Your Understanding Statement:
In this study, the placebo is…
a. Incorrect. In a different study of oral medication
it could be a pill, but in this study testosterone is
being given as a gel that is applied to the skin, not
a pill taken by mouth.
b. Incorrect. In this study the placebo is a gel that
will seem identical to testosterone gel but will not
have testosterone, or any other medication, in it.
c. Correct.
d. Incorrect. A device is not being used in this
study.
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The following things will happen
at each visit….
• Your height, weight, waist,
hips and blood pressure will
be measured
• Your blood will be drawn (2
tubes, which is about 3
tablespoons)
• How far you walk in 6 minutes
will be measured
• A rectal exam to check the
size of your prostate and for
the presence of nodules will
be done (at Months 3 and 12)

Slide 50

You will be asked about ….
• the medicines that you take
(prescription and over-thecounter drugs and herbal or
supplements)
• health events, by asking you
to describe new health
problems that you have or
changes to conditions that
you already have. You will be
asked if you had a heart
attack or stroke, but should
report all of your health
problems.

Slide 51

You will be asked about ….
• trouble urinating
• difficulty doing
ordinary things like
washing up in the
morning or grocery
shopping

Slide 52

You will be asked about ….
• any falls you may
have had and what
happened

• your memory, and
you will do tests to
see what you
remember

V1.20080627
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You will be asked about ….
• depression and
moods
• your interest in sex
• your feelings of
energy and tiredness
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You will be asked to….
• respond to a few questionnaires
at home using a phone system
that lets you answer questions in
the privacy of your home (or
anywhere).
• The sexual diary, tiredness,
depression and mood
questionnaires will be done at
home using this system.
• You will be taught how to use
this phone system, called IVR,
by the research staff.
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What is Interactive Voice Response (IVR)?
IVR is a computer based phone
response system. You may have used
a similar system when calling the gas
or electric company.
Recorded messages will guide you
through the steps of answering the
questions. You will use the phone
number pad to answer them.
Your answers will be stored in an
electronic computer file by your study
code number. Your voice will not be
recorded.
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Check Your Understanding
A rectal exam is being
done to check for colon
cancer.

True
False

It is not important to report
changes in health
conditions like diabetes,
since it is not related to
taking testosterone.

True
False

Check Your Understanding
You will be asked to report
all of the medicine that
you take, even over-thecounter medicines.
You should not report
trouble urinating because
that happens to most men,
as they get older.
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False

True
False
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Check Your Understanding Statement:
A rectal exam is being done to check for colon
cancer.
True. Incorrect. A rectal exam is being done to
check for prostate enlargement and the presence
of nodules in the prostate.
False. Correct. A rectal exam is being done to
check for prostate enlargement and the presence
of nodules in the prostate.
Check Your Understanding Statement:
It is not important to report changes in health
conditions like diabetes, since it is not related to
taking testosterone.
True. Incorrect. All of the changes in your health
status are important to report. This may be
informative about what is happening to all of the
men in the study.
False. Correct. All of the changes in your health
status are important to report. This may be
informative about what is happening to all of the
men in the study.
Check Your Understanding Statement:
You will be asked to report all of the medicine that
you take, even over-the- counter medicines.
True. Correct. It is important to report as
accurately as possible all of the medicine that you
take, even over the counter medicines.
False. Incorrect. It is important to report as
accurately as possible all of the medicine that you
take, even over the counter medicines.
Check Your Understanding Statement:
You should not report trouble urinating because
that happens to most men, as they get older.
True. Incorrect. You should report any problems or
changes that happen to the way you urinate.
False. Correct. You should report any problems or
changes that happen to the way you urinate.
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Check Your Understanding
You will respond to
questions using the IVR
system by….
a. Speaking slowly so your
voice can be recorded
b. Using the number pad on
the phone
c. Using a computer to go
to a website

Check your
answer here.
a. □
b. □
c. □
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Risks and Benefits

Slide 60

What are the risks of this study?
There is a chance that using testosterone
may make some conditions worse. You
will be checked for these before and
during the study.
The risks that you should understand are
described in the following slides:

Slide 61
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Prostate cancer
There could be small areas
of cancer in the prostate that
are not harmful and are not
causing a health problem to
you now. Using testosterone
could change these small
prostate cancers that are not
harmful, into harmful ones.
Presently, there is not
enough information to know
about the effects of taking
testosterone on prostate
cancer.

60

Check Your Understanding Statement:
You will respond to questions using the IVR
system by….
a. Incorrect. Your voice will not be recorded in the
IVR system.
b. Correct. You will use the number pad on the
phone to answer questions.
c. Incorrect. It is not necessary to use a computer
to answer these questions. You will use the
number pad on the phone to answer questions.

Testosterone Trial Informed Consent Education Program - Appendix A

Slide 62
You will have rectal exams to check
your prostate, and blood tests to
learn your PSA result, which is the
prostate cancer blood test. You will
be asked questions about your
prostate health and medical history.
Your prostate and the risk of
developing prostate cancer will be
monitored closely over the course
of the study. Regular screening
such as the kind you will receive in
this study, helps detect prostate
cancer in its early stages.

Slide 63

Benign Prostatic Hyperplasia (BPH)
BPH is the condition of having an
enlarged prostate gland. Using
testosterone may increase the size of
the prostate, which could cause a
decrease in urine flow.
You may see this as difficulty in starting
and finishing when you urinate.
Presently there is not enough
information to know about the effects of
taking testosterone on BPH. You will be
checked for this condition throughout the
1st year. The research team will act on
changes that you report by referring you
to the study urologist.

Slide 64

Slide 65
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High red blood cell count
Testosterone normally increases
the number of red blood cells, which
is why men have higher red blood
cell counts than women.
It is possible that using testosterone
could increase the number of red
blood cells that you have to higher
than normal. This might increase
the chance of stroke.
During the 1st year, your blood
count will be checked frequently.
Increases above normal will be
investigated. You may be told to
use less gel or you may be told to
stop using the testosterone gel
altogether.

Sleep apnea
Testosterone may increase the risk
of sleep apnea, a condition in which
not enough oxygen gets into the
blood during sleep. This may result
in excessive daytime sleepiness.
The connection between
testosterone and sleep apnea is not
known, so you will be asked about it
regularly.
If you have been told that you have
sleep apnea you can be in the study
only if you are being treated for it.
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There is some risk in doing
the study tests. It may be
hard for you to do the
walking test or climb the
stairs. The study staff will be
there to assist you at all
times, but you can rest or
stop at any time.
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Having blood taken from
you has a small risk of
temporary mild pain,
bruising or infection. It is
possible that you could faint.
There will be trained
technicians to draw your
blood.
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You may feel it is hard to
answer some questions
because they are so
personal.
All of your answers are
considered private and will
not be shared with anyone.
The information that you give
will be given a code number.
Your name or other personal
information will not be
connected to your answers.

Slide 69
You may find that the
memory tests are tiring.
You should just try to do
the best you can.
There are no passing or
failing grades on these
tests, and you should not
practice taking these
tests at home to do
better.
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Using Testosterone Safely
There are safety precautions
that you must follow when
using testosterone gel.
You must be careful not to
allow others to touch the gel on
your skin.
It is important to wash your
hands, allow the gel to dry
completely after you put it on,
and to keep the skin covered.

Slide 71
If a prostate biopsy is
needed, there are risks of
bleeding and infection. You
will be given detailed
instructions before the
procedure to reduce these
possibilities.

Slide 72
Lastly, there is a chance that there are side
effects that are not yet known.

Slide 73

Benefits
You may not get any benefit
from being in this study. You
may feel better or stronger, or
you may not.
By being in this study, you
may help medical science
gain a better understanding
of testosterone treatment.
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Check Your Understanding
Changes in the prostate will be
checked by measuring the PSA level
in your blood, doing a rectal exam
and asking questions about
urinating.

True
False

Testosterone may cause an increase
in the number of red blood cells.

True
False

Check Your Understanding
Using testosterone will make
you physically stronger.

True
False

Using testosterone may enlarge
your prostate gland.

True
False

64

Check Your Understanding Statement:
Changes in the prostate will be checked by
measuring the PSA level in your blood, doing a
rectal exam and asking questions about urinating.
True. Correct. Measuring the PSA level in your
blood, doing a rectal exam and asking questions
about urinating are procedures that monitor you for
changes in your prostate cancer risk and
enlargement of your prostate.
False. Incorrect. Measuring the PSA level in your
blood, doing a rectal exam and asking questions
about urinating are procedures that monitor you for
changes in your prostate cancer risk and
enlargement of your prostate.
Check Your Understanding Statement:
Testosterone may cause an increase in the
number of red blood cells.
True. Correct. Testosterone may cause an
increase in the number of red blood cells. This
may not occur, may be small or could be
significant. This will be monitored over the course
of the study and may require a change in the dose
or discontinuation of testosterone gel.
False. Incorrect. Testosterone may cause an
increase in the number of red blood cells. This
may not occur, may be small or could be
significant. This will be monitored over the course
of the study and may require a change in the dose
or discontinuation of testosterone gel.
Check Your Understanding Statement:
Using testosterone will make you physically
stronger.
True. Incorrect. It is not known for certain that
testosterone will improve your physical strength.
False. Correct. It is not known for certain that
testosterone will improve your physical strength.
Check Your Understanding Statement:
Using testosterone may enlarge your prostate
gland.
True. Correct. It is possible that testosterone could
make your prostate become enlarged. This may or
may not happen to you.
False. Incrrect. It is possible that testosterone
could make your prostate become enlarged. This
may or may not happen to you.
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Check Your Understanding
Using testosterone will cause
you to have sleep apnea.

True
False

You will have a prostate biopsy
at the end of the study.

True
False
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More Important Information
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Will you be paid for being in this
research study?
You will be paid a small
amount of money, which
will be given to you as you
complete study visits.
You will be reimbursed for
travel expenses and
parking.
You will be given coupons
for meals while you are at
the research clinic visits.
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Check Your Understanding Statement:
Using testosterone will cause you to have sleep
apnea.
True. Incorrect. The connection between
testosterone and sleep apnea is not clear.
False. Correct. The connection between
testosterone and sleep apnea is not clear.
Check Your Understanding Statement:
You will have a prostate biopsy at the end of the
study.
True. Incorrect. You will not automatically have a
prostate biopsy at the end of the study. A prostate
biopsy may be done if the prostate cancer risk
signs (your PSA level and rectal exam) change. A
urologist will determine if you should have a
prostate biopsy.
False. Correct. You will not automatically have a
prostate biopsy at the end of the study. A prostate
biopsy may be done if the prostate cancer risk
signs (your PSA level and rectal exam) change. A
urologist will determine if you should have a
prostate biopsy.
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What if you want to leave the research
study after you begin?
You can leave the
study at any time.
Dropping out of the
study will not interfere
with your future care.
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Will confidential health information be
collected as part of this study?
Some private information about your health will be
collected like your medical history, and your answers to
questions about your physical function, sexual function,
and other questionnaires.
All information (including blood samples) collected in this
study is kept strictly private by using study code numbers
to collect information instead of names.
This code number will be on the blood samples and
questionnaires and in the computer that saves your
responses.
Your contact information will be locked securely in files
at the research clinic and used only by the staff to
contact you.
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The information collected in the study is saved in
a highly secure computer system. Only those
people who are working to analyze the
information will be able to look at it.
Authorized study representatives may review
and copy data collected from this study and your
medical records. Your name will never appear in
any articles that are published of the results from
this research.
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What will you do with the blood
you collect?
Any blood that is left over after
measuring testosterone, PSA and
other tests will be saved at the
Mayo Clinical Trial Services
Central Laboratory for 5 years or
more.
These saved samples might be
helpful in the future, if new tests
are discovered that would enhance
knowledge about testosterone.
You will not be able to find out
anything about these tests.
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What happens if you are injured during
the study?
If you are injured because of
taking part in this research
study, you should contact the
study doctor or staff right away
at the phone numbers provided
on the front page of this form.
They will advise you about
what to do to next.
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What if you have questions about the
study?
Your rights and protection as a
research participant are very
important.
If you have any questions, concerns
or complaints about this research
study, or if you have questions about
your rights as a research subject, feel
free to contact the Principal
Investigator listed on the front page of
this form.
You may also call your Institutional
Office of Regulatory Affairs with any
question, concerns or complaints.
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Check Your Understanding
Blood samples that are taken for the
study will be saved for several years.
To protect your personal information,
the study will use study code
numbers, secure computer
technology and restrict access to
study information to authorized
personnel.
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True
False

True
False

Check Your Understanding Statement:
Blood samples that are taken for the study will be
saved for several years.
True. Correct. Such samples may be useful for
future research studies.
False. Incorrect. Such samples may be useful for
future research studies.
Check Your Understanding Statement:
To protect your personal information, the study will
use study code numbers, secure computer
technology and restrict access to study information
to authorized personnel.
True. Correct. Your personal information will be
kept confidential.
False. Incorrect. Your personal information will be
kept confidential.
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Check Your Understanding
You will be paid a lump sum of
money at the end of the study.
If you have a complaint about
this research study, you may
not contact anyone but the
research study staff.
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True
False

Check Your Understanding
If you start the study, it does
not matter if you leave before
you finish all of the research
study visits.
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True
False

True
False

68

Check Your Understanding Statement:
You will be paid a lump sum of money at the end
of the study.
True. Incorrect. You will be paid as you complete
certain research visits. Your travel expenses and
meals will be provided.
False. Correct. You will be paid as you complete
certain research visits. Your travel expenses and
meals will be provided.
Check Your Understanding Statement:
If you have a complaint about this research study,
you may not contact anyone but the research
study staff.
True. Incorrect. Your rights as a research
participant are very important. You may contact
the investigator, staff, the office of regulatory
affairs and/or research administration at this
institution to discuss your concerns.
False. Correct. Your rights as a research
participant are very important. You may contact
the investigator, staff, the office of regulatory
affairs and/or research administration at this
institution to discuss your concerns.
Check Your Understanding Statement:
If you start the study, it does not matter if you
leave before you finish all of the research study
visits.
True. Incorrect. You are free to leave the study at
any time without effect to your healthcare.
However, it is best to collect a complete set of
information about your participation for the entire
length of the study study whenever possible.
False. Correct. You are free to leave the study at
any time without effect to your healthcare.
However, it is best to collect a complete set of
information about your participation for the entire
length of the study study whenever possible.
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Summary

Slide 89
• The Testosterone Trial is being done to
find out if older men who take testosterone
will have improvement in walking, more
interest in sex, improved memory and
improved energy level.
• There are 4 trials in this research study
focused on:
•
•
•
•

Slide 90
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Physical Function
Sexual Function
Memory
Energy

If you decide to be in the study, you will ...
• be in the study for 2 years.
• use testosterone or placebo gel every day
for 1 year.
• go to 7 research clinic visits in the first
year.
• report regularly about your health status
and medicines.
• use an automated phone system to
answer questions from home.
• be asked personal questions.

During research clinic visits, you will …
• take a walking test.
• have your height, weight, waist, hips and
blood pressure measured.
• have blood drawn.
• have a rectal exam (at Month 3 and 12).
• be asked questions about physical ability,
sexual interest, your memory and energy
level.
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You will be monitored for changes in …
•
•
•
•
•

your prostate size and PSA.
your red blood count.
how you urinate.
how you sleep.
other medical conditions that are new to
you, and changes in those that you have
known about.
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• There may be risks involved in taking
testosterone that are not known.
• If you start the study and then decide to
leave, it will not have an affect on your
health care.
• If you have concerns about your rights as
a research participant, you may contact
the investigator, research staff, and the
office of regulatory affairs or research
administration.
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If you have questions or concerns…
Please discuss them with
someone from the
research team.
You may want to discuss
this research study with
your spouse or significant
other as well as with your
doctor.

Slide 95

Comments?
We appreciate your
feedback!
If you would like to
make comments
about the tutorial,
please do so by
clicking the box on
the right.
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Write comments here.
____________________
____________________
____________________
____________________
____________________
____________________
____________________
____________________
____________________
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Conclusion
Thank you for using this program
and for considering participating in
this research study.
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Administrative Section
Tutorial management toolkit View Check Your Understanding output.
View Comments.
View audit trail.
Check version control.
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Sample Output –
Check Your Understanding
Q1

□ Printer Friendly
Q4

Q5

Q6

Introduction

NA

NA

NA

Participating in the Trial

NA

NA

NA

Module

Q2

Q3

4 Testosterone Trials in 1
Tests and Procedures

NA

Risks and Benefits
More Important Information
Comments
NA – Not Applicable
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INFORMED CONSENT DOCUMENT
CONSENT TO PARTICIPATE IN A RESEARCH STUDY
Study Title: The Testosterone Trial
Main Study Consent Form
P.I. Name and Department
Co-P.I. Name(s)
Telephone Numbers(s), 24-Hour Emergency Number
IRB # of Protocol
Sponsor: National Institute on Aging
Invitation to Participate
You are being invited to take part in a research study. The Testosterone Trial is a
research study in men over the age of 65 who have a low blood level of the main male
hormone, testosterone. This research study is being done to see if taking testosterone
for one year will improve walking, sexual function, memory, and energy.
This is a consent form. The information in this consent form will tell you about what will
happen during the study and the possible risks and benefits, so that you can decide
whether or not to participate. The form also includes other important information about
the research study, including the health information we will collect. Please read this form
carefully before deciding whether you want to take part. If there is anything you do not
understand, please ask questions.
Participation in this research study is voluntary. You do not have to take part in this
study if you do not want to. If you do take part, you can leave at any time.
The National Institute on Aging (NIA) of the National Institutes of Health (NIH) and
Solvay Pharmaceuticals are providing most of the funding for this study. This study will
be conducted at 18 sites in the United States. The University of Pennsylvania,
Philadelphia, PA, will manage the study.
It is expected that 1200 men will take part in this study. Each man’s participation will last
two years.
Why am I being asked to take part in this study?
You are being invited to take part in this study because you are 65 years of age or older
and have complaints or symptoms that might be related to a low testosterone level.
Testosterone is a hormone produced by the testes and is responsible for the
development of normal male muscles, bone strength, energy level, and sexual function.
In many men the amount testosterone in their blood gradually decreases with age.
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Some research suggests that this fall in testosterone might cause some of the
unwanted effects of aging.
What is the purpose of this research study?
The main purpose of this research study is to determine if taking testosterone improves
walking, sexual function, memory, and energy levels of men with low testosterone.
Other purposes are to find out if testosterone treatment improves the ability to perform
daily activities, improves mood and lowers the tendency to fall.
How long will I be in this research study?
If you qualify, you will take part in the study for 2 years. During the first year you will
receive treatment with testosterone or with a placebo, which looks like medication but
does not have the active ingredient in it. Also during the first year you will come to the
research clinic for seven visits for different types of testing, and you will also answer
questions from home by telephone. During the second year you will come to the
research clinic once and answer questions by telephone once.
What is involved in this research study?
The first step is to find out if you qualify to take part in the study. You will be eligible if
your blood testosterone is low, if you have a problem that could be caused by low
testosterone, and if you do not have a problem that testosterone treatment could make
worse. If you qualify for one or more of the four separate studies (called trials) that are
part of this study, you will take part in the trials that you choose. The four trials are
called:
Physical Function Trial
Sexual Function Trial
Cognitive Function Trial
Vitality Trial
You will be treated for one year. During this year you will be tested for the possible
desirable and undesirable effects of testosterone. During the year after treatment, you
will be followed to make sure that your general health remains good. The following
sections describe the clinic visits, tests and procedures in this study.
Eligibility
The test results from Screening Visits 1 and 2 show that you qualify for one or more of
the four separate trials. If you agree to participate, you will move to the next step and
take a few more tests at the Baseline Visit at the research clinic.
Study Treatment Assignment
If you agree to participate, you will be assigned to one of two treatment groups. One
group will receive testosterone in a gel which is applied to the skin every day. The other
group will receive a matching placebo gel, which does not contain testosterone. (The 2
gels will appear the same, but one will have testosterone in it and the other will not.)
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You will be assigned to a treatment group by a computer program. Neither you, the
study doctors, nor the study staff will know if you are assigned to the group that is
treated with testosterone or the group that is treated with the placebo.
How Will I Take the Treatment
Testosterone gel and placebo gel both come in an upright tube with a pump on top.
The gel is applied once a day. You will push down on the pump with one hand and will
catch the gel (which is a combination of alcohol and water) in the palm of the other
hand. Both gels look, feel and smell the same. You will then spread the gel on the skin
of your abdomen, chest or upper arm. After letting the gel dry, which usually takes
about 2-3 minutes, you should wash your hands. You must cover the area where the gel
is applied, because it is very important to keep the testosterone from touching anyone
else. This is especially important for women or children, who might develop male
features, such as facial hair, if they were exposed to testosterone.
The Four Trials
If you are eligible for more than one trial, you may choose to participate in only one trial
or as many trials for which you qualify and are interested in. Some tests will be given to
all participants in the study. Other tests will be given only to those who take part in a
particular trial. The following is an explanation of the tests used in each of the four
trials.
1. Physical Function Trial: We will measure how far you can walk in a certain period of
time. Another test is a measure of stair climbing. There are also questions about daily
physical function.
2. Sexual Function Trial: The tests in this trial will be questionnaires about your ability
to have sex and erections. One of them you will answer from home by telephone, and
the others you will complete at the research clinic.
3. Cognitive Function Trial: The tests in this trial will be about your memory, such as
how well you can remember a paragraph that is read aloud to you by someone and how
well you can remember designs and drawings.
4. Vitality Trial: The test in this trial will be a questionnaire about your energy level that
you will answer from home by telephone. Other tests will be questionnaires about mood
and emotional state that will be done at the research clinic.
Description of Tests and Procedures
The list below describes each test and procedure that will be done during the course of
the study. The tests are grouped by those everyone will have, followed by tests that are
only for those taking part in a specific trial.
Interactive Voice Response (IVR)
Some of the tests involve questionnaires. Some of the questionnaires you will answer
with paper and pencil at the research clinic, and others you will answer from home using
a computer-based telephone system called IVR. For IVR, recorded messages will
guide you through the questions. You will answer the questions using the phone
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number pad. Your answers will be kept in a secure computer file by a code number that
cannot be traced back to your name or other private information.
Tests for Everyone in All Trials
Most of the tests and procedures will happen every 3 months when you come to the
research clinic. The table on the last page shows what will happen each time you come
to the research clinic and when we call you on the phone between visits.
Blood Draw
Blood will be taken once a month for the first 3 months and then every 3 months.
Testosterone will be measured each time. Prostate-specific antigen (PSA), a blood test
for prostate cancer, will be measured at baseline, 3 and 12 months. Hemoglobin (a test
for red blood cells) will be measured every three months.
Physical Measurements
We will measure your height, weight, waist, hips and blood pressure.
Rectal Exam
This exam involves putting a gloved finger in the rectum, to feel for hardness or lumps in
the prostate. It will be done at the 3 and 12 month visits.
Walking Test
You will be asked to walk for 6 minutes down a corridor at a normal pace. The distance
you walk and how fast you walk will be measured.
Your Medicine
You will be asked to bring all of the medicines (prescription, over-the-counter and herbal
or supplements) you are taking to the research clinic at each visit. We will also ask
about medicines during monthly phone calls.
Health Problems and Changes
You will be asked to describe new health problems that may have happened or changes
to conditions that you already have at each visit and phone call.
Urination Questions
You will be asked a few questions about problems with passing urine.
Activities of Daily Living
You will be asked about difficulties in general activities of daily living, such as bathing or
making lunch, as well during the previous month.
Falls
You will be asked if you have experienced a fall during the previous 3 months.
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General Memory Test
You will be asked questions that test your memory and thinking at baseline and at 12
months.
Memory Questions
You will be asked 6 questions about your memory compared to when you were
younger. This test will be done at this screening visit in everyone and after 12 months
in those participating in the Cognitive Function Trial. This test will take less than 5
minutes.
Memory for Words
Two paragraphs will be read aloud to you by someone and you will be asked what you
remember. This test will be done every 6 months.
Sex Diary
You will be asked 6 questions about your sexual activity and feelings using the IVR
phone system. This test will be done once a day for 7 days and repeated every 3
months.
Depression Questions
You will be asked several questions about whether you feel depressed. You will use the
IVR phone system to answer these questions.
Good and Bad Mood Questions
You will be asked questions that are about your mood. You will use the IVR phone
system to answer these questions.
Tiredness Questions
You will be asked questions about your energy level and tiredness. You will use the IVR
phone system to answer these questions.
Change in the Way You Feel
You will be asked to compare how you feel now to how you felt at the start of the study.
Tests for Participants in the Physical Function Trial Only- given every 3 months
Stair Climbing Test
You will be asked to climb a standard (12-step) staircase at your normal pace.
Physical Function Questions
You will be asked questions about how you can move and your physical abilities.
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Tests for Participants in Sexual Function Trial Only- given every 3 months
Erection Questions
You will be asked questions about your ability to have erections and sex.
Function Questions
You will be asked questions about your sexual thoughts and activities.
Tests for Participants in the Cognitive Function Trial Only- given every 6 months
Memory for Designs Test
You will be asked to remember designs that you have been shown from memory.
Memory for Drawings Test
You will be asked to pick out a drawing that you are shown from a set of many other
drawings.
Connect the Dots Test
You will be asked to connect lines between numbered and lettered points on a page.
Tests for Participants in the Vitality Trial Only- given every 3 months
Quality of Life Questions
You will be asked how you feel about your quality of life in several areas. This test has
11 questions. This test will be done using the IVR phone system.
Different Moods Questions
You will be asked about your mood and feelings of anger from a list of words that
describe different ways that you might feel. This test will be done using the IVR phone
system.
Study Schedule
The chart below shows the schedule of tests during the time that you are in the study. In
the 1st year there are 7 research site visits and 6 phone contacts. In the 2nd year there is
1 research site visit and 1 phone contact.
Study
Phase

Treatment Phase (1 Year)
Monthly Clinic Visits or Phone Contacts

Visits

Base
line

Contact
Type

C

M1

M2

M3

M4

M5

M6

M7

M8

M9

M 10

M11

M12

M18

M24

C

C

C

P

P

C

P

P

C

P

P

C

C

P

C = Clinic visit in person; P = phone contact
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The research clinic visits and phone calls, and the tests and questionnaires that will be
done are listed below.
Baseline Visit
For everyone:
Blood draw (2 tablespoons)
Measurements of height, weight, waist, hip, blood pressure
Rectal exam
Walking test
Medicines you are taking
Health problems and changes
Questionnaires at the research clinic about urinating, daily activities, falls,
memory and mental sharpness
Questionnaires at home using IVR phone system about interest in sex,
depression, moods, tiredness and mental sharpness
For men in specific trials:
Physical Function Trial: stair climbing test and physical abilities questionnaire
Sexual Function Trial: questionnaires at the research clinic about erections and
sexual function and questionnaires at home using IVR phone system about
sexual thoughts and interest
Cognitive Function Trial: questionnaires at the research clinic about memory for
designs and drawings
Vitality Trial: questionnaires at home using IVR phone system about moods and
feelings about your quality of life
At the baseline visit you will be given the study gel and you will be shown how to use it.
This visit will take 3 – 4 hours.
Months 1 and 2 Visits
At these visits you will be asked about the following:
Blood draw (1 tablespoon) for testosterone level only
Medicines you are taking
Health problems and changes
You will be asked to bring your used study gel container with you to these visits and we
will review the instructions for gel use.
These visits will take about 30 minutes.
Month 3 Visit
You will be asked to bring your used study gel container with you to this visit and we will
review the instructions for gel use. We will do the following tests and questionnaires with
you:
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All Participants
Blood draw (2 tablespoons) for testosterone level, PSA, hemoglobin and
hematocrit
Measurements of height, weight, waist, hip, blood pressure
Rectal exam
Walking test
Medicines you are taking
Health problems and changes
Questionnaires at the research clinic about urinating, daily activities, falls,
memory and mental sharpness
Questionnaires at home using IVR phone system about interest in sex,
depression, moods, tiredness and mental sharpness
For men in specific trials:
Physical Function Trial: stair climbing test and physical abilities questionnaire
Sexual Function Trial: questionnaires at the research clinic about your erections
and sexual function and questionnaires at home using IVR phone system about
your sexual thoughts and interest
Vitality Trial: questionnaires at home using IVR phone system about your moods
and feelings about your quality of life
This visit will take 2 1/2 – 3 1/2 hours.
Months 4 & 5 Phone Contact
You will be contacted by telephone for these visits. The following assessments will
occur for all subjects:
Medicines you are taking
Health problems and changes
Review of instructions for using the study gel
These calls will take approximately 15 minutes.
Month 6 Visit
You will be asked to bring your used study gel container with you and review the
instructions for gel use. We will do the following tests and questionnaires with you:
All participants:
Blood draw (2 tablespoons) for testosterone level, hemoglobin and hematocrit
Measurements of height, weight, waist, hip, blood pressure
Walking test
Medicines you are taking
Health problems and changes
Questionnaires at the research clinic about urinating, daily activities, falls,
memory and mental sharpness
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Questionnaires at home using IVR phone system about interest in sex,
depression, moods, tiredness and mental sharpness
For men in specific trials:
Physical Function Trial: stair climbing test and physical abilities questionnaire
Sexual Function Trial: questionnaires at the research clinic about erections and
sexual function and questionnaires at home using IVR phone system about your
sexual thoughts and interest
Cognitive Function Trial: questionnaires at the research clinic about your memory
for designs and drawings
Vitality Trial: questionnaires at home using IVR phone system about your moods
and feelings about your quality of life
This visit will take 3 – 4 hours.
Months 7 & 8 Phone Contact
You will be contacted by telephone for these visits. The following assessments will
occur in all participants:
Medicines you are taking
Health problems and changes
Review of instructions for using the study gel
These phone calls will take approximately 15 minutes.
Month 9 Visit
You will be asked to bring your used study gel container with you to this visit and we will
review the instructions for gel use. We will do the following tests and questionnaires with
you:
All participants:
Blood draw (2 tablespoons) for T level, hemoglobin and hematocrit
Measurements of height, weight, waist, hip, blood pressure
Walking test
Medicines you are taking
Health problems and changes
Questionnaires at the research clinic about urinating, daily activities, falls,
memory and mental sharpness
Questionnaires at home using IVR phone system about interest in sex,
depression, moods, tiredness and mental sharpness
For men in specific trials:
Physical Function Trial: stair climbing test and physical abilities questionnaire
Sexual Function Trial: questionnaires at the research clinic about your erections
and sexual function and questionnaires at home using IVR phone system about
your sexual thoughts and interest
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Vitality Trial: questionnaires at home using IVR phone system about your moods
and feelings about your quality of life
This visit will take 2 1/2 – 3 1/2 hours.
Months 10 & 11 Phone Contact
You will be contacted by telephone for these visits. The following assessments will
occur for all participants:
Current medicines
Health problems and changes
Review the instructions for using the study gel
These phone calls will take approximately 15 minutes.
Month 12 – End of Treatment Visit
This is the last visit of the treatment phase. You will be asked to bring your used study
gel container with you to this visit. We will do the following tests and questionnaires with
you:
All participants:
Blood draw (2 tablespoons) for testosterone level, PSA, hemoglobin and
hematocrit
Measurements of height, weight, waist, hip, blood pressure
Rectal exam
Walking test
Medicines you are taking
Health problems and changes
Questionnaires at the research clinic about urinating, daily activities, falls,
memory and mental sharpness
Questionnaires at home using IVR phone system about interest in sex,
depression, moods, tiredness and mental sharpness
For men in specific trials:
Physical Function Trial: stair climbing test and physical abilities questionnaire
Sexual Function Trial: questionnaires at the research clinic about erections and
sexual function and questionnaires at home using IVR phone system about
sexual thoughts and interest
Cognitive Function Trial: questionnaires at the research clinic about your memory
for designs and drawings
Vitality Trial: questionnaires at home using IVR phone system about your moods
and feelings about your quality of life
This visit will take 3 – 4 hours.
Months 18 Assessment
The follow-up visit at Month 18 may be held at the research clinic or at home.
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Blood draw (1 tablespoon) for PSA
Health problems and changes
Months 24 Assessment
The follow-up visit at Month 24 will be by phone to ask about health problems and
changes.
What are the risks of taking part in this research study?
Risks of testosterone treatment
Because testosterone might make certain conditions worse, if you take part in this study
you will be tested before and during treatment to check for these conditions and to try to
reduce the risk to your health. These are the conditions that testosterone might make
worse.
Prostate cancer. About half of men over age 65 have tiny areas of cancer in their
prostate glands that appears not to hurt them. The worry is that testosterone treatment
in this study could change these harmless tiny prostate cancers into harmful ones.
When testosterone was given in previous studies to older men, there was not an
increase in prostate cancer, but there is not enough research about older men using
testosterone to know for certain how it will affect the chance of prostate cancer. Also,
some men who have prostate cancer have an improvement in the cancer if their blood
testosterone is lowered.
Men who have had prostate cancer or a pre-cancerous condition called PIN (prostate
intra-epithelial neoplasia) will not be in the study. To reduce the chance that men who
are in this study could have a worsening of an unknown cancer, only men who have a
less than a 30% chance of any prostate cancer and less than a 7% chance of an
aggressive prostate cancer will be allowed to be in the study. These possibilities will be
figured out by using a combination of blood PSA results, age, race, family history of
prostate cancer, absence of a prostate lump, and any results of a prior prostate biopsy,
(sticking a needle into the prostate to get a sample to look at under the microscope) if
one was done. Also, only men who do not have a prostate lump or hardness on the
rectal examination will be in the study, unless a previous biopsy shows that the lump is
not cancer.
If your rectal exam does not show a lump, your estimated risk of any prostate cancer is
about _____% and of aggressive (called high grade) prostate cancer is about _____%.
To check men in this study, we will repeat the blood PSA test at 3 and 12 months of
treatment and again 6 months after stopping treatment. If the blood PSA level
increases by a certain amount, and the same result is found when we measure it again,
we will recommend that you see a urologist to discuss whether you should have a
prostate biopsy. At that time, the urologist will go over with you the risk of having a
prostate cancer compared to the problems of treatment for prostate cancer if one is
found.
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Enlarged prostate (Benign prostatic hyperplasia/BPH). Testosterone treatment of older
men might also increase the size of the prostate and cause a decrease in urine flow.
Other studies of testosterone treatment have not shown worsening of urination
problems, but the number of men studied so far is too small to know for sure. To
reduce the chance of urination problems in this study, only men who do not have a lot of
difficulty urinating will be eligible. This will be known by the score on the urination
questionnaire. These questions will be asked again at 3 and 12 months. If the score
goes up by 5 or more points, that will lead to us check for the cause of this problem.
High red blood cell count (Erythrocytosis). Testosterone normally increases the number
of red blood cells, which is why men have higher red blood cell counts than women.
However, if a man had a high red blood cell count when his testosterone was low,
increasing the blood testosterone could increase his red blood cell count to higher than
normal. This might increase the chance of a stroke. For this reason, only men with
blood hemoglobin levels (a measure of red blood cells) below a certain value will be
allowed to be in the study. In addition, the hemoglobin levels will be checked again at 3,
6, and 12 months. An increase above normal will lead us to send you to another doctor
to find out the cause of the increase. If no cause is found, the amount of gel that you
use will be reduced. If the hemoglobin value does not go back to normal within one
month, treatment will be stopped.
Sleep apnea. Testosterone may increase the risk of sleep apnea, a condition in which
not enough oxygen gets into the blood during sleep, resulting in excessive sleepiness
during the day. Although it is not certain that testosterone has this effect, men who
have been diagnosed with sleep apnea will be eligible only if they are being treated for
it.
Procedure Risks
Physical Function Tests. There is a risk that you may find the Walking Test or the Stair
Climbing Test tiring or too hard to finish. Trained personnel will be there to check how
you are during these tests. You may stop the test if you need to rest. You may also
stop to rest if you become tired because of the number of tests.
Blood Draw. Getting your blood drawn at the research clinic has a very small risk of
temporary mild pain, bruising or infection at the place where the needle was stuck in the
blood vessel. There is also the possibility of fainting because of anxiety or fear of
needles. These risks are decreased by the use of trained people to draw your blood.
Questionnaires. Because some of the questionnaires are personal, some men may feel
uncomfortable answering these questions. The most personal questions will be asked
over the phone IVR system while you are at home so that you will have privacy. Your
answers will not be shared with anyone. All information that is collected will be
considered private and only identified by a study code number.
Memory Tests. Testing of your memory may be stressful and tiring because they
require you to think hard sometimes. We just want you to try your best. There are no
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passing or failing grades on these tests, and you should not practice taking these tests
at home to do better.
Testosterone Gel. If testosterone gets transferred from your skin to a woman’s or a
child’s skin, she or he could develop male features. Transfer can be avoided by washing
your hands. It is also important to allow the gel to dry thoroughly after applying it, and to
keep the area where the gel was applied covered. The gel contains alcohol and in
some men may cause dry skin or skin irritation.
Prostate Biopsy. If a prostate biopsy is needed, it has two main risks, which are
bleeding and infection. The standard safety measure to lower the chance of bleeding is
to avoid medicines that thin your blood and prevent it from clotting normally, like aspirin,
anti-inflammatory medicines (such as ibuprofen), and herbal supplements, before and
after the procedure. The standard safety measure to lower the chance of infection is to
give antibiotics. If you have a prostate biopsy, your doctor will give you complete
instructions about taking antibiotics. By using these safety measures, the chance of
bleeding or serious infection requiring hospitalization is less than 1%.
Unknown risks. There is also a chance of a side effect that is not known at this time.
Are there any benefits to taking part in this research study?
You may not get any benefit from participating in this study. You may feel better or
stronger, or you may not. Your health status will be checked frequently during the time
that you are in the study. By taking part in this study you may improve our
understanding of testosterone treatment.
What happens if I decide not to take part in this research study?
You are free to decide whether or not to be in this study. Your care at this institution will
not change if you choose not to be in this study or if you choose to withdraw from the
study anytime after you start.
How long will I be in the study? What if I want to leave the research study after I
begin?
You will be in the study for 2 years. You are free to leave the study at any time.
Dropping out of the study will not interfere with your future care.
Will confidential health information be collected as part of this study?
Some private information about your health will be collected. There are forms that ask
questions about your medical history, physical function as well as sexual function,
memory and how you think, and your energy level and quality of life. Every attempt will
be made to keep all information collected in this study strictly private. Authorized
representatives of [Insert Institution], the University of Pennsylvania, and the National
Institutes of Health may review and copy information collected from this study and your
medical records. If any articles are published from the results of this research, you will
not be identified by name.
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What happens to the health information if you want to leave the study?
If you leave from study, no additional information will be collected. Information that has
already been collected and are part of the study will remain. You may ask that your
stored blood samples be destroyed by writing a request to the Principal Investigator of
the study.
What will you do with the blood you collect?
Blood that is left over after measuring the testosterone, PSA and other tests will be stored
at the Mayo Clinical Trial Services Central Laboratory. It may be used for future studies
of the effects of testosterone. Information that identifies the blood as yours will be
removed, so that the only connection of the blood to your study results will be a study
code number, which you will be given at the time of you consent to be in the study. The
blood will be stored through the end of the study, up to 5 years or more. It may be used
at any time during that period for other studies of testosterone effects. It is possible that
new tests might be available in the future, which could be useful in understanding
testosterone. You will not be able to find out the results of these tests.
Researchers who plan to use your blood sample for future research studies will ask
permission from the National Institutes of Health and the investigators of this study
before using your sample. Samples will be released only to scientists who are qualified
and prepared to conduct a research study.
What will it cost me to take part in this study?
It will not cost you anything to be in the study. You will be contributing your time and
energy.
Will I be paid for taking part in this research study?
You will be paid a small amount, which will be given to you as you complete study visits.
If you complete the entire study, the total amount will be $750. In addition, you will be
reimbursed for travel expenses and parking and you will be provided meal tickets during
the study visits.
{This section can be customized per site.}
What happens if I am injured during the study?
In the event of a research-related injury, please contact your study doctor right away at
the phone numbers provided on the front page of this form.
In the event of any physical injury resulting from the research procedures, medical
treatment will be provided without cost to you, but financial compensation is not otherwise
available from {Customize this section in accordance with institutional policy.}
You or your insurance company, if any, may be billed for medical expenses associated
with this study only if they are believed to be medically necessary and not related to the
study. {Customize this section in accordance with institutional policy.}
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What if I have questions about the study?
If you have questions, concerns or complaints about being in this research study, or if
you have any questions about your rights as a research subject, you should speak with
the Principal Investigator listed on page one of this form. If a member of the research
team cannot be reached or you want to talk to someone other than those working on the
study, you may contact the {Institutional Office of Regulatory Affairs} with any question,
concerns or complaints at Your Institution by calling {XXX)YYY-ZZZZ}.
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SIGNATURE PAGE
I have had this research study explained to me. I have read the informed consent form.
I have had the chance to ask questions. My questions have been answered to my
satisfaction.
I understand that my signature below means that I voluntarily agree to take part in the
research study. I will be given a copy of this form for my records.

Printed Name

Signature of Subject

Date

(Or Legally Authorized Representative – note relationship to subject)

Printed Name

Signature of Witness

Date

(Only required if the subject cannot read this consent form)
I have discussed this clinical study with the subject and/or his authorized representative,
using language that is understandable and appropriate. I believe that I have fully
informed the subject of the nature of this study and its possible benefits and risks.

Printed Name

Signature of Person Obtaining Consent

Date

SEPARATE SIGNATURE REQUIREMENTS FOR OPTIONAL GENETIC SAMPLE
We are also interested in collecting blood samples to store for future genetic studies.
Details of the genetic sub-study are described in the attached genetic consent form.
You are not required to take part in this portion of the study in order to be in the main
part of the research study.
Please indicate your interest in participating below:

Please Initial

Yes, I would like to know more about the genetic sub-study. If I decide
to take part in the sub-study, I will sign a separate consent form.
No, I do not want to participate in the genetic sub-study.

Please Initial
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Study Schedule
Test or Procedure in All Participants
(Visit Type: C = Clinic Visit, P = phone contact)
Informed consent
Blood draw
Your medicine
Medical history
Health problems & changes
Gel instruction and review
Height, weight, waist, hip, blood pressure
Rectal exam
Urination questions
Walking Test
Short memory test
Sex Diary – Question 4*
Memory for words
Tiredness questions
Change in the way you feel
Activities of daily living
Falls
Depression questions
Mood questions*
Joint pain and stiffness questions
Sexual function questions
Nervousness and worry questions
Memory questions
Word knowledge test ‡
Tests in Participants in Specific Trials:
Physical: Physical Function Questionnaire-10, Stair climb
Sexual: Sex Diary* (complete), Erection questions, Sexual
function questions
Cognitive: Memory of designs, drawings, connect the dots,
general memory†
Vitality: Quality of life questions*, Different mood questions*
(Key: * administered by IVR, † 0 and 12 mos, ‡ 0 mo only)
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MULTIMEDIA TOOL DEVELOPMENT PROPOSAL – April 4, 2008
Title

Development of an Informed Consent Multimedia Tool for Research

Introduction Proposed Use

This multimedia tool is being developed to accompany the informed consent
document of a clinical trial in a geriatric population. Its purpose is to enhance
the informed consent process by presenting the information in the informed
consent document in a series of brief, focused teaching modules. These
modules will include video and audio technology to guide the user through the
module. Each module will conclude with a review section called “Check Your
Understanding’ that asks the user to answer questions about the information
that have just seen and heard. A summary of these responses will be made
available to the research team presenting the informed consent document to
provide a basis for review and clarification of the information presented in the
module.

Audience

The users of this multimedia tool will be the potential participants of the
Testosterone Trial, a clinical trial of testosterone efficacy in men aged 65 and
older.

Resources

Funding for development of this tool will be sought from the research study
sponsor. Research technology expertise will be contracted through the web
services development department in the University of Pennsylvania School of
Medicine.

Personnel

Dated April 4, 2008

Content will be developed by a collaborative team of the following:
-

Denise Cifelli, Project Director. Ms. Cifelli, Director of Project Operations and
Compliance in the Clinical Research Computing Unit, has led the project
development effort from the proposal phase and will continue to direct the
project into the implementation phase. She has developed the study
protocol, informed consent documents, regulatory documentation and
associated monitoring and quality assurance plans.

-

Peter J. Snyder, MD. Principal Investigator of the Testosterone Trial. Dr.
Snyder is an endocrinologist at the University of Pennsylvania, School of
Medicine and has conducted testosterone clinical research for over 30
years. He will serve as the subject matter expert for the content presented in
the tutorial.

-

Gregg Fromell, MD, Director, Office of Human Research, University of
Pennsylvania, School of Medicine. Dr. Fromell provides expertise on
research education and training, research compliance and quality
improvement. He will serve as the subject matter expert on the essential
elements of informed consent, readability and format of the material.

-

Barry Dornfeld, PhD. Educational Media Consultant. Dr. Dornfeld of the
Center for Applied Research (CFAR) provides expertise in development of
content and organization of biomedical knowledge and serves as a reviewer
of the multimedia tool.
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Content
Development

The content of the tutorial will parallel the information written in the informed
consent document. Subject matter experts will review the tutorial for accuracy
regarding the testosterone trial (Snyder), the essential elements of informed
consent (Fromell) and overall tone, sequencing, cohesion and clarity (Dornfeld).
The tutorial has been developed as a Powerpoint presentation. See Appendix
A. This presentation will serve as the template for the development of the tool
as a teaching module available from a secure server as well as a portable
program.

Availability of
Technology

The tutorial will be developed for use by participants who may access it from a
web site on a secure server (hosted at the University of Pennsylvania
Biomedical Research Computing environment) on the internet. This will be
made available via a computer in a private location at the research clinic to
serve those participants who are willing to read the informed consent and
participate in the informed consent process during the baseline clinical research
visit.
The program must also be available on transportable media (DVD) so that a
participant may take the DVD home to read the informed consent document and
complete the accompanying tutorial in the privacy of their home, using a
standard desk top computer. The requirements for the desk top computer must
be of the type that are available on most recent model computer systems and
not require “plug-ins” or files that must be downloaded in order to run the
tutorial.

Technology
Features

The tutorial must include the following features:
1. Advance organizer. The first slide of the tutorial will instruct the user
about the features of the tutorial described below. Audio will accompany
this first slide as the mouse moves automatically over the features and
tags appear to indicate the alternative keystroke that will perform the
same function as the mouse. The second slide of the tutorial will
describe the Check Your Understanding slides and features using the
same audio and video technology.
2. Table of Contents. Each segment of the module must be listed
separately in a vertical table of contents so that it can be selected by
one click of the mouse or keyboard stroke and begin at the first slide of
that segment.
3. Video streams must be sharp and clear. An indicator will appear over
the video file and a tag will instruct the user to click the arrow to play the
video.
4. Volume adjustment keys with mouse-over tag to describe the function.
5. Slide navigation keys to return to the previous slide or advance to the
next slide.
6. Repeat slide key.
7. Slide counter to indicate slide number of total slides. (Example: Slide 3
of 10).

Dated April 4, 2008
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8. Quit program key. This will allow the user to stop the tutorial and save
their responses so that they can resume later and continue from that
point.
9. Check Your Understanding features will include the ability to click in a
response check box and receive immediate reply indicating if response
is correct or incorrect and accompanying information. (See Comment
boxes on these slides as an example.)
10. Responses to Check Your Understanding questions will be saved in a
data table that can be generated as a report at the end of the program
by the participant (if using the program at home) or by the person
administering the tutorial (if the process is occurring at the research
clinic.) This table should include complete information (the entire
question, answers and explanations) be viewable and printable so that it
may be used to discuss the informed consent issues that require clarity.
11. The program must allow the user to pause or quit the program and
resume where he left off, saving the responses completed to that point.
Additional
Requirements

The tutorial will be provided to the software developer and programmer as a
power point presentation. Video images and video streams will be provided and
incorporated into the tutorial as indicated in the .ppt file. The project director will
have final approval over the selection of the audio portion of the program. (The
audio portion must be a male voice.) The functionality (described above) will be
pilot tested by the project director before final implementation.

Terms

To be determined.

Timeline

To be developed.

Contact
Information

Denise Cifelli
cifelli@mail.med.upenn.edu
Phone 215-573-4534

Dated April 4, 2008
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INTERVIEW QUESTIONS FOR POTENTIAL TESTOSTERONE TRIAL
PARTICIPANTS (MEN 65 OR OLDER)
EVALUATION OF INFORMED CONSENT DOCUMENT INTERVIEW SCRIPT
Dated: February 9, 2008
Interviewer: I would like to ask your opinion about several things that have to do with a
research study that is being planned at several medical centers in the US. It is about the
use of testosterone in men aged 65 or older.
Testosterone is not a new drug. It has been available for a few years and doctors can
prescribe it. Doctors are conducting this study to try to find out if using testosterone (it is
often called “T”) leads to improved physical performance (for example: ability to walk,
climb stairs, carry groceries), increased interest in sex, improved memory and improved
overall sense of energy and zest for life.
Before starting in the study there would be a few tests that must be done to check your
testosterone level and other blood tests, as well as questionnaires that you will be asked
to complete. For now, I would like to ask you 15 questions about the research consent
form that I will give you to read.
Interviewee initials: ___ ___ ___
1.

Are you willing to participate in this interview? ....................................... Yes No

2.

Age __________ years

3.

Level of education:
th
1 6 grade or less
th
th
2 7 to 12 grade, no high school diploma
3 High school graduate or equivalent (e.g. GED)
4 Technical or vocational school degree
5 Some college education, but not completed degree
6 College graduate
7 Professional or graduate degree (e.g. Master’s, PhD, JD, MD)

Directions: I am going to give you several pages to read. It is an informed consent
document that describes the research study. Please take your time and read it and
let me know when you are finished.
4.

On the line below, please rate how easy or difficult it was for you to read the
informed consent document.

1
Very easy

2
Easy

3
Somewhat
easy

4
Moderate

5
Somewhat
difficult

6
Difficult

7
Very
difficult

Comments: _________________________________________________________
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After reading this document, do you understand that you could be in 1, 2, 3 or 4
separate trials depending on the information you give when asked about your
physical abilities, sexual interest, memory or energy? ........................... Yes No

Comments: _________________________________________________________
6.

A. Do you understand the explanation about the testosterone gel and placebo
(gel without medication) used in this study? ......................................... Yes No
B. Do you understand that you will not know which gel you are using and that
the study doctors, nurses or other study staff members will not know either? ....
.............................................................................................................. Yes No

Comments: _________________________________________________________
7.

Do you understand the explanation about using the gel every day for a year and
the steps that you should take to be sure that you use it safely?........... Yes No

Comments: _________________________________________________________
8.

Do you understand the commitment that is being asked of you to in coming to the
research site for tests and questionnaires 6 times over the first year and once
during the second year?......................................................................... Yes No

Comments: _________________________________________________________
9.

A. Do you understand what the IVR phone system is used for? .......... Yes No
B. What do you think of using your home phone (or cell phone) to answer private
questions?

Comments: _________________________________________________________
10.

Do you think you will be able to answer personal questions about your physical
abilities, sexual life, memory and energy with the people at the research site?...
.............................................................................................................. Yes No

Comments: _________________________________________________________
11.

A. Do you understand the risks of being in this study? ......................... Yes No
B. Do you have concerns about the risks of taking testosterone? ........ Yes No

Comments: _________________________________________________________
12.

A. Do you think being in this study is the kind of thing that you would be
interested in doing? ............................................................................... Yes No
B. Would you be willing to talk about it with your spouse, partner, family or
friends?.................................................................................................. Yes No

Comments: _________________________________________________________
13.

Do you think it would be helpful to discuss this study with your own doctor? ......
.............................................................................................................. Yes No

Comments: _________________________________________________________
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A. If the information in the consent form were given to you on a CD, would you be
able to use a home computer or DVD player to view it?
i. Computer? ................................................................. Yes No
ii DVD player?................................................................. Yes No
B. If you were given a link to a website, would you feel comfortable reading this
on the Internet? ...................................................................................... Yes No

Comments: _______________________________________________________
15.

Do you have any questions or comments about this informed consent document,
the research study or any other topics related to this discussion?........ Yes No

Comments: _______________________________________________________
Thank you very much for your time and for discussing this topic with me!!
Notes:
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EVALUATION OF INFORMED CONSENT DOCUMENT
SUMMARY DATA AND COMMENTS
Interview with Potential Subjects about the Testosterone Trial

Dated: April 16, 2008
1. Respondents (n = 8)
Initials
1
2
3
4
5
6
7
8

ALC
BLM
PLH
ABP
LAD
RMC
RSR
MIK

Age

Eligible?

77
67
71
65
75
70
80
85

No
Yes
No
Yes
Yes
Yes
No
Yes

2. Education
Number
(Percent)

Level of Education

1 (12.5%)
4 (50%)
1 (12.5%)
2 (25%)

7th to 12th grade, no high school diploma
High school graduate or equivalent (e.g. GED)
Some college education, but not completed degree
College graduate

3. Age Group
Range: 65 – 85
Number
Age
(Percent)
65 - 74
4 (50%)
75 - 85
4 (50%)

20080416
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4. Document Readability
Number
(Percent)

Document Readability

1 (12.5%)
2 (25%)
2 (25%)
2 (25%)
1 (12.5%)

Very easy
Easy
Somewhat easy
Moderate
Somewhat difficult

Question
Question
Number
5.
6 A.
6 B.
7.
8.
9.
10.

11 A.
11 B.
12 A.
12 B.
13.
14 A.
14 B.
14 C.

20080416

Knowledge of 4 separate trials about your physical
abilities, sexual interest, memory or energy
Explanation about the testosterone gel and placebo
Knowledge of treatment or placebo group
Medication use and safety precautions
Time commitment and trial participation schedule
IVR phone system
Comfort regarding personal questions about physical
abilities, sexual life, memory and energy with
research staff.
Risks
Specific concerns about testosterone risks
Potential interest
Willingness to discuss with your spouse, partner,
family or friends
Discuss this study with personal physician
Ability to use technology at home – computer
Ability to use technology at home – DVD player
Ability to use technology at home – Internet website

Yes

No

6 (75%)

2 (75%)

8 (100%)
7 (87%)
8 (100%)
6 (75%)
6 (75%)
7 (87%)

0
1 (13%)
0
2 (75%)
2 (25%)
1 (13%)

8 (100%)
6 (75%)
4 (50%)
6 (75%)

0
2 (25%)
4 (50%)
2 (25%)

8 (100%)
3 (38%)
4 (50%)
2 (25%)

0
5 (62%)
4 (50%)
6 (75%)

